Interactions in a Drug-Target Network by Kulkarni, Varsha S.
INTERACTIONS IN A DRUG-TARGET NETWORK 
 
 
 
 
 
 
 
 
 
 
Varsha S. Kulkarni 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
 Doctor of Philosophy  
in the School of Informatics and Computing,  
Indiana University                                                                                                                   
December 2016 
 ii
 
Accepted by the Graduate Faculty, Indiana University, in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy. 
 
Doctoral Committee 
 
_____________________________________  
David J. Wild, PhD 
 
_____________________________________  
Gerardo Ortiz, PhD 
 
_____________________________________  
John Beggs, PhD 
 
_____________________________________  
Y.Y. Ahn, PhD 
 
 
April 18, 2016 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
 
 
 
 
  
 
To 
my father 
Suresh N. Kulkarni 
for introducing me to the world of learning 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you to my loved ones to have nurtured the ethos  
that academic pursuits promote intellect and excellence in a humanistic way. 
 
 
 
 
 
 
 
 
 
 
 iv 
 
Acknowledgments 
 
I am very thankful to Prof. David Wild for his encouragement of my work and efforts. 
Completion of a doctoral dissertation is interesting and often a challenging process. Prof. 
David Wild’s advice, kindness and support helped me reach the finish line.   
 
I am grateful to Profs. Gerardo Ortiz, John Beggs, Y.Y. Ahn for helpful discussions and 
comments on this dissertation. I thank Prof. Ying Ding for discussions and all those staff, 
students, and faculty at Informatics and Computing who have helped me in this program. I 
gratefully acknowledge the financial support of my research through assistantships, 
fellowships, and instructorships at Indiana University. 
 
I also thank Prof. Anatole Beck of the University of Wisconsin-Madison for his 
encouragement, and for the confidence he showed in my capability. 
 
In addition, I thank the professors and scholars at all the institutions I have studied. 
Collaborations and discussions with them have significantly contributed to my academic 
advancement. 
 
 
 
 
 
 
 
 
 
 v
 
Varsha S. Kulkarni 
INTERACTIONS IN A DRUG-TARGET NETWORK 
 
Highly chemically similar drugs usually possess similar biological activities but small changes in 
chemistry result in large differences in biological effects. Chemically similar drug pairs showing 
extreme deviations in activity represent distinctive drug interactions. The presence of these 
interactions adversely affects prediction of structure and activity associations. Their identification has 
crucial implications on drug development and innovations. Given the multitude of drugs in an 
ensemble, pairs possess multilevel distinctiveness in terms of their attributes of structural and activity 
similarity or variation. The cliff characterization for describing drops in similar activity has received 
considerable attention, however, it remains quantitatively less refined. In this dissertation, I investigate 
distinctiveness of drug interactions using a large drug-target network and provide a quantitative 
rationale for characterization of the pharmacological topography. I consider rises in pairwise similarity 
and variation in activity of drugs on proteins with chemical similarity (c) to assess levels of 
distinctiveness. These activity measures are affected by the presence of few drugs (targets) having 
multiple targets (drugs). I quantify interactions between drugs by considering similarity and variation 
jointly with c. The probability of distinctiveness is predicted by employing joint probability of 
structure and activity measures. Intermittent spikes in variation along the axis of c represent canyons 
in the activity landscape. This new representation accounts for distinctiveness through relative rises in 
activity measures and offers an enhanced perspective. It provides a mathematical basis for predicting 
the probability of occurrence of distinctiveness. It identifies the drug pairs at varying levels of 
distinctiveness and non-distinctiveness. Prediction is validated even if data approximately satisfy the 
conditions of the formulation. The difference in distinctive interactions emphasizes the importance of 
studying both measures, and reveals that the choice of measurement can affect the interpretation.  
 vi 
Further, I find that minor changes in methods or perturbations of measures can crucially alter the 
classification of interactions as distinctive. Identification and interpretation of distinctiveness, 
therefore, gain relevance through methodological specifications. The present analysis of structure and 
activity provides an in depth modeling and assessment of distinctiveness and the probability of its 
occurrence. It could potentially influence decision-making in research and development. 
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Chapter 1 
 
INTRODUCTION 
 
I. Context 
 
The field of drug discovery primarily constitutes creation of new medicinal compounds having 
targeted therapeutic impacts for improvement of human health. It entails identification of optimum 
combination of physicochemical properties that can cure diseases and ailments of diverse nature 
observed. The drugs are prepared using the physicochemical properties specified according to [1,2] a 
procedure that emphasizes the importance of select properties required for the medicinal compounds. 
However, with the development of an increasing number of drugs, the process seems to have favored 
few properties. A study conducted on a group of chemists showed that majority of chemists based 
their strategy on two or three properties if not less [1]. This bias that magnifies with time may in part 
be attributed to the cumulative discretionary decisions of the drug manufacturers, scientists and 
chemists involved in the process.  
This complexity in drug discovery gives rise to a variety of interactions or associations between pairs 
of drugs. In a system of drugs, an interaction between two drugs is a connection, which usually refers 
to the similarity or dissimilarity of their activities on protein targets. In other words, two drugs are 
connected depending on whether they have a common or an uncommon target [3,4]. However, there is 
a dimension to an interaction between drugs in addition to the one based on their activities. Pairs of 
drugs can also be connected through the level of similarity (or dissimilarity) in their chemical or 
structural properties [5]. These two dimensions of pairwise interactions of drugs together account for a 
various structure-activity associations observed between drugs. These associations are crucial for 
understanding drug development and studied extensively by researchers [1,2,5,6]. Consider that a 
person is looking to cure a common ailment and A is the standard medicine s/he is aware of. Someone 
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claims that medicine B is as good as A. [7-12] Now the person has two alternatives1 . Further 
inspection of the chemical constituents of A and B shows little variation. Hence, A and B are 
chemically analogous and it is not surprising that they are substitutes having similar therapeutic 
actions. S/he finds another medicine C which is chemically analogous to A and B. It should be 
obvious then that there are three alternatives for the cure2 . However, it turns out that C has a 
therapeutic action different from A and B. While the connection between A and B is a usual or 
expected, the one between A and C or B and C is unusual.  
These kinds of connections between pairs of drugs that possess similar chemical compositions but 
highly variant physiological activities often occur in drug development. Extreme deviations in activity 
of pairs of chemically similar drugs describe distinctive connections or interactions between pairs of 
drugs. Distinctive interactions occur between pairs of drugs with high chemical similarity and activity 
variation, or, high chemical similarity and low activity similarity. The presence of these kinds of 
interactions is known to adversely affect the prediction of activity changes of drugs caused by changes 
in their chemical structures. Identification of such interactions can significantly improve drug 
development. However, given the multitude of drugs in the ensemble, pairwise associations potentially 
have multilevel attributes (of structural and activity similarity or variation). Thus distinctiveness can 
be found at varying levels, which makes it challenging to identify the distinctive interactions. This 
dissertation focuses on selective identification of distinctive interactions by employing rigorous 
quantitative techniques. It attempts to understand the extent to which this classification of distinctive 
versus non-distinctive depends on the choice of measurement. It would help in knowing the 
                                                        
1 The price of drugs can be a determinant of the drugs chosen by individuals [7,8] and there are socio-economic 
considerations on the distribution of health care, medicines that would affect their usage [9-11]. Further, an 
increased availability of some chemical combinations in the market decreases the effectiveness of drugs prepared 
for limited, advanced treatments. Thus, financial incentive of the drug industry can potentially affect the health 
outcomes. 
2 This decision is further dependent on the growth of medical innovations in the society [10]. The individuals’ 
choice of new health products is often influenced by and dependent on certain aspects of the social network and 
the properties of the innovation [12].  
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significance of the classification in the context of the methodology and govern the quantitative 
assessments, and the health outcomes. 
 
 
II. Previous research 
 
The kinds of connections between drugs described above as usual, are those interactions that conform 
with the similarity principle in medicinal chemistry [13]. According to this principle, a pair of 
structurally similar drug compounds tends to behave similarly on proteins. This, however, is not 
indicative of their behaviors on proteins in general. The proteins targeted by a pair of structurally 
similar drugs may not necessarily be similar in their chemical composition. Distinctive interactions 
refer to those pairs of drugs that do not conform with the similarity principle. This principle is of vital 
significance because pharmacologists are constantly in search of variants of lead substances to make 
drugs that do not vary in behavior, cure the same kinds of ailments or are active on the same proteins 
[1-6, 13, 14]. This achieves substitution with little cost particularly for substitutes not very different 
from the original compound. Further, it affects the pricing of the variants or substitutes in the market. 
If a small structural change in the drug achieves a similar therapeutic impact, it comes at low cost, and 
that would allow a substitute to be introduced at a similar price. On the contrary, if one has to widen 
the search in the chemical space to find a variant in order to achieve a similar functionality, the typical 
cost incurred is high. 
This can also work in another way. If diversity between chemical compounds is limited, then 
according to similarity principle, many substitutes so generated would add neither to the knowledge 
base nor to the range of therapeutic outcomes. Thus, it may be a difficult decision because a small and 
simple modification tends to churn out a vast number of substances that can be possibly derived. A 
small change in chemical space resulting in substantially different functional behavior is also helpful, 
from the perspectives of both drug discovery and marketability. For instance, if a structural analog 
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produced has many targets, it can be helpful for increasing drug applicability3 [1,3,4]. Thus, structure 
activity analysis is crucial for understanding pharmacological outcomes. It is an important tool for 
predicting how the non-synthesized drugs would act on proteins based on the knowledge of functional 
behaviors of a given ensemble of drugs. In fact, the decisions surrounding the identification of the 
magnitude of change in chemical structure required to produce a desired change in functionalities, are 
still made informally by pharmacologists using their experience and knowledge [1, 15]. A quantitative 
analysis of structure and activity is meant to assist in making rigorous and accurate decisions and 
experimental design. 
The functionality of a drug indicates its physiological activity (on a protein, for instance), if it is active 
or inactive. Structural properties of compounds are governed by the physicochemical properties that 
determine that they would to be active on certain proteins and inactive on others. The activity may be 
measured as success in a drug’s ability to bind with a protein or cure a disease or affect genes, among 
others. Structure activity relationship [1,2,14] is formalized as the modification in physiological 
activity of a drug resulting from a modification in its chemical constitution or chemical structure. It 
can be written as ∆ℎ
 
 = ∆ℎ .  
The quantitative structure activity analysis uses a training data sample from which one can extract 
information on changes in activity caused by changes in structure. The patterns obtained from the 
analysis are then applied to predict the activity outcomes of a test sample of data on drugs and proteins 
[1,14,16]. As this involves analysis of the data, a suitable application of statistical and mathematical 
techniques becomes critical. The development of sound and effective quantitative structure activity 
models for the analysis and prediction in diverse data samples is a major area of research in the fields 
of cheminformatics, computational chemistry, medicinal chemistry, drug discovery. These models are 
designed for investigating the space of interactions of drugs through changes in structure and 
                                                        
3 This implies that existing drugs can be profiled for curing diseases in addition to those they are intended to 
treat. The marginal effect of a chemical innovation on the biological activity can vary in a wide range, and the 
large effects can lead to inventions in medicine as the entire chemical space is explored. 
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corresponding activities. The space of interactions defined by the structures and activities of drugs is 
an activity landscape. The activity landscape is a two dimensional space on which drug interactions 
may be mapped as the similarity in physiological activity between two drugs with the corresponding 
similarity in their chemical structure or composition. Thus the interactions between a pair of drugs 
may be quantified in terms of two properties or quantities- chemical or structural similarity and 
similarity (or variation) in their functionalities. In the activity landscape, researchers have identified 
regions along the chemical space where there is a huge drop in similar activity. The extreme deviations 
in activity observed for pairs of drugs that are highly chemically similar are represented as 
discontinuities in the landscape. These interactions have been quantified as activity cliffs [7,8] in 
previous research. Their presence hinders the prediction of quantitative models and therefore it is 
important to identify them and the regions of the landscape where they are observed.  
 
III. Toward a new characterization of the activity landscape 
 
Are pairs of structurally analogous drugs similar in their activities or not? Which drug interactions are 
distinctive and which of them conform with the similarity principle? How probable is their occurrence 
in a given data sample? This forms the basis for studying multilevel interaction effects in an ensemble 
of drugs, which I focus on in this dissertation. Structure activity analysis requires two properties for all 
pairwise interactions. It may either condition the functionality based on a constant structural similarity 
or condition the structural similarity based on constant functionalities. Therefore, all the pairwise 
interactions can be quantified at multiple levels of each of the two attributes (i) chemical similarity (c) 
and (ii) similarity or variation in activity. Similarity (s) and variation (d) in activity of a pair of drugs 
are measured respectively as the number of common and uncommon targets of theirs. Here, I use data 
on biological activity of 1354 drugs on 1596 proteins. These are drugs listed in drugbank database. 
The information is stored as a bipartite graph. In this graph, connections are between two types of 
vertices. A link from a drug to a protein indicates that the protein is an active target of that drug. The 
information on activity is entered in a 1354×1596 adjacency matrix. The existence of a connection 
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implies activity and the corresponding element of the matrix is 1 whereas absence of a connection 
implies inactivity with corresponding entry of 0. Targets of a drug are the proteins that it is active on. 
The binary information of a drug’s activity on all proteins stored in the form of an array constitutes the 
activity profile of the drug. Next, I obtain data on pairwise chemical similarity of all the drugs in the 
ensemble. The chemical structure of a drug compound is based on molecular combinations having 
physicochemical properties. The structural representations of compounds are encoded by descriptors 
of these properties. The descriptors are in the form of binary strings, wherein the presence and absence 
of a feature are given by 1 and 0 respectively. The degree of structural resemblance of a pair of drugs 
is quantified by a coefficient of chemical similarity (c) of their strings. Chemical similarity is 
computed using the widely applied Jaccard coefficient as this has been shown to be effective.  
Activity cliffs are formed by pairs having both high c and low similarity in their activity values 
[17,18]. On the landscape it is expected that as c increases, similarity in physiological activity would 
also increase. Interestingly, some pairwise drug interactions deviate from this behavior. Activity cliffs 
are commonly observed in almost all data collections on structure and activity of drugs. Researchers 
have focused particularly on using quantitative models to account for such aberrations [14-18]. 
However, they consider s and d as complementary measures of activity. Cliffs are quantitatively 
characterized using differences in activity values and the chemical similarity of drugs. In this 
dissertation, I use two measures of activity, s and d (number of common and uncommon targets) and 
consider each of these jointly with c for every interaction. These measures quantify the interacting 
system approach. I find intermittent rises in both measures, particularly, d in the landscape. This leads 
to a canyon characterization of the landscape. The distinctive rises in d and s along the chemical space 
represent distinctive and non-distinctive interactions at varying levels. Further, in this new 
representation the level of distinctiveness exhibited by a pair can vary according to multiple levels of c 
in combination with those of d or s. I compute the probability of distinctiveness using joint probability 
of finding a pair with particular levels of attributes c, s, d. This can be used to predict the occurrence of 
distinctive interactions in the landscape.  
 7
 
IV. Main Contributions 
 
This analysis verifies the presence of multilevel distinctiveness using a large collection of drugs 
through the distribution of pairs in various levels of (combinations of) c and s, c and d. I quantify 
aggregate (non) distinctiveness with the distribution of pairs in various levels of c and s or d. 
Quantitative modeling has advanced the structure activity analysis significantly in drug discovery but 
there has not been a mathematical treatment for accurate interpretation of regularities and irregularities 
in the landscape. Studies have relied on less precisely constructed measures for quantification of cliffs 
in the landscape. In fact, the existing quantitative structure activity analysis in this field is insufficient 
for analyzing cliffs and some of the methods applied are not well defined. The effort to increase the 
level of sophistication and technicality in quantitative assessment of the landscape brings to fore the 
lack of a precise specification of the abrupt deviations in activity or the distinctiveness. In this 
dissertation, I give a rationale for defining distinctive interactions and predicting the probability of 
their occurrence. The formulation here consists of predicting the probability of distinctiveness of a pair 
of drugs using the probability distributions of c, s, d. This approach facilitates identification of 
distinctiveness using both measures s and d and prediction of how it varies in the landscape. An aim of 
the dissertation is to introduce the subjectivity inherent in the quantitative interpretation of 
distinctiveness. It is intriguing to find little consensus on the interpretation yielded by similarity and 
variation, and different scales of their measurements. The canyon characterization offers an accurate 
classification of distinctiveness in relation to the technique applied. This would facilitate efficacious 
use of drugs for specified treatments and achieve improved health of the society. 
A challenge to the analysis of structure and activity in drug discovery is that the magnitude of the data 
available [19] affects the inferences. Differences in sizes of the data samples are known to affect 
estimation and hence the interpretations. This can significantly distort the inferences about activity 
cliffs and distinctiveness in the activity landscape. For instance, the power law pattern of probability 
distributions of number of targets per drug and drugs per target has been verified for drug-target data 
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[3, 20]. Power law behavior indicates heterogeneous nature, that some drugs (proteins) possess (are 
targets of) many more targets (drugs) than average. The drug target data studied in this dissertation 
also conform with this behavior. However, different data samples may display variations in this 
behavior and the extent of heterogeneity. This can affect the pairwise measurements s and d and their 
distributions. It is, therefore, worthwhile to find that the predicted probability formulation derived in 
this thesis is valid for data that may not be exactly identical in nature to the sample used for its 
construction. This is the main merit of the approach. It is based on multilevel interaction effects of c, s, 
d and gives the probability of distinctiveness for every pair of drugs.  
Hence, I show that an accurate interpretation of the landscape for distinctive interactions is in relation 
to the methodology used to analyze it. While structure activity relationships have been quantified 
using advanced statistical techniques, this aspect of the subjectivity of landscape interpretation and its 
implications for identifying distinctive interactions has largely been ignored in literature. Studying 
both measures s and d enhances our perspective on this problem while contributing to the adaptive 
meanings of distinctiveness. Few drug interactions, however, would remain consistently distinctive but 
a lot of them may be susceptible to a methodological modification, and this should be considered. This 
study recommends a targeted choice of methods that is consistent with the nature of distinctiveness 
being addressed by a researcher in a particular context. 
 
V. Outline  
 
The rest of the dissertation is organized in four chapters. Chapter 2 provides a detailed mathematical 
analysis of the bipartite graph of drugs and protein-targets. It shows distributions of drugs per target 
and targets per drug. I also calculate the probability distribution of number of drugs that a drug has at 
least one common target with. These findings help to assess how a few multi-target drugs can possibly 
govern the measures of interaction that I subsequently analyze in this work. I begin the study of 
distinctive interactions using the network of drugs. Chapter 3 extends the network analysis to 
understand distinctive drug-drug interactions using weighted measures of c, s, d. I study how 
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connections between pairs of drugs are distributed in multiple levels of distinctiveness, while pointing 
out the effect of employing s and d measures on the interpretation. I conclude this chapter with 
inferences on distinctiveness based on the measures used as compared to previously established 
research and a discussion of the limitations of the previous analyses. In chapter 4, I introduce the 
formulation of predicted probability of distinctiveness in the landscape using a canyon 
characterization. I enunciate the merits of this characterization (which implements distinctiveness 
through both activity measures) and the probabilistic analysis which accurately predicts the occurrence 
of distinctive interactions at various levels. I identify the distinctive interactions using both measures 
and discuss the differences and the central contributions. I end the dissertation in chapter 5 giving an 
auxiliary analysis of the data using some information theoretic measures. This is another form of 
comparing the effectiveness of activity measures for classification of interactions as distinctive, the 
inherent uncertainty. It shows a possible ranking scheme of rareness of distinctive interactions based 
on probabilities of occurrence of the levels of interaction attributes c, s, d. Finally, in the conclusion of 
this thesis, I reflect on the main themes emerging from this analysis. I discuss how this analysis can 
enhance the understanding on distinctiveness in the activity landscape, thereby contributing to 
pharmacological practice and research.  
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Chapter 2 
 
CONNECTIONS IN A DRUG NETWORK 
 
 
A network is a graph of vertices and links connecting them. This thesis focuses on the evaluation of 
connections between drugs. A network of drugs as vertices forms a useful tool for this study of 
interactions between drugs. This provides the perspective of an interacting system. In a bipartite 
graph, there are links connecting vertices of two types. The bipartite graph of drugs and protein targets 
has links from drugs to proteins signifying that the drugs are active on those proteins. This information 
on activity can be used to construct a network of drugs, so that a pair of drugs is connected if both 
drugs have one or more common targets. Alternatively, a network can be constructed where pairs of 
drugs are connected because they have uncommon targets. Thus, two drugs can interact because of 
their common or uncommon activity. It is also known that all pairs of drugs are connected through 
their structural similarities. Pairwise associations of activity and structure of drugs reflect the structure 
activity relationship. In this chapter, I give a preliminary drug network analysis and study how it 
contributes to our understanding of distinctive interactions.  
 
2.1 Data 
I use the information on activity of  =1354 drugs on ′ =1596 protein targets. The activity 
information is binary, Ai(k)=1 if a drug i is active on protein k and 0 if it is inactive (i = 1,2…,1354; k = 
1,2,….1596). This constitutes the activity profile of drug i. I use chemical similarity of all pairs of 
drugs. As explained above, structural representation of a drug is in the form of physicochemical 
descriptors encoded in a binary string. The descriptors chosen here are in accordance with extended 
connectivity fingerprints (ECFP) [1,2,5,6,21]. This is because ECFP descriptors include a wide range 
of features. The similarity between the strings of two drugs is computed by employing the Jaccard 
coefficient. The chemical similarity of all pairs of drugs specifying the weight of the link between two 
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drugs is provided in C as  ×  weighted adjacency matrix. The elements of the matrix, Cij give the 
chemical similarity of the pair of drugs i, j and 0 ≤ "# ≤ 1.  
2.2 Network of Drugs and Protein Targets 
The connections between pairs of drugs in a network are formed according to whether or not they have 
any common or uncommon targets in their profiles. Therefore, it is useful to observe the distributions 
of number of drugs per target and number of targets per drug. This is because if there are drugs with 
many targets, they may form connections with many drugs through commonality of a target. On the 
other hand, if there is a target on which many drugs are active, it reflects the presence of many 
pairwise connections. Therefore, drugs having many (few) connections in the network indicate 
increase (decrease) in similar activity, and if their connections are highly chemically similar, these 
interactions (do not) conform to the similarity principle. If connections between drugs are formed 
through the non-commonality of their targets, then drugs having many (few) connections in the 
network indicate decrease (increase) in similar activity, and if their connections are highly chemically 
similar, these interactions are (non) distinctive. The probability patterns of drugs per target and targets 
per drug are plotted in Figs.2.1, 2.2 on a logarithmic scale. Pareto power law behavior is evident,  
%&~&(), k being the number of targets per drug or drugs per target4. * ≈ 2 implies possibility of a 
very high variance in sizes of activity profiles [22, 23], however, the exponent may be different for 
different samples of data analyzed. The presence of power law implies heterogeneity in terms of 
[3,19,20,22] how drugs bind to proteins and proteins react to drugs. This means that some drugs tend 
to be active on many more proteins than average and few targets are acted on by many more drugs 
than average. Multi-target drugs are beneficial as they can treat ailments of diverse nature [1].  
                                                        
4 Power law behavior is expressed as %&~&(). This can be approximated by the equation,  log % ~ −* log&. The coefficient of regression line on the log-log plot of log % versus log& gives the power law 
exponent *.  
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Mathematical research on networks has proved some useful quantities for understanding network 
structure in the context of both unipartite and bipartite random graphs with arbitrary degree 
distribution [22, 23]. These graphs are considered random in the sense that the degrees of all vertices 
are independent and identically distributed. In the present drug-target network of N drugs and ′ 
proteins, if a drug is active on an average of 1 proteins and a protein has on an average 2 drugs 
functionally active on it, then  
13 = 2                      2.1. 
It is observed in the data that 1 ≈ 3.77, 2 ≈ 3.2. From Figs.2.1, 2.2, the overall behavior of drug 
activity and protein response may be formalized as the normalized probability of a drug being active 
on (a protein responding to) &6 proteins (&7 drugs) which is 
%8&69 ≈ &6():(;<=:>): ?( @=:A                          2.2    
%&7 ≈ &7()B(;C=>)B ?( @=BA                          2.2D.    
In both equations (2.2a,b), the constants E@, EF denote the exponential cut-off parameters5. >)G is 
the polylogarithm function and *@, *F are the power law exponents computed from the data.  
I analyze the characteristics of the drug network wherein two drugs are connected or linked if they are 
jointly active on a protein. Theoretically, this is done using the formulations of generating functions 
established in previous research. The results derived using these are analyzed for certain specific kinds 
                                                        
5 The Eqs. 2.2 a,b are variants of power law behavior representing heavy tails of power law. In situations like 
these, or when the data is limited, the upper range of the tail is truncated using an exponential cutoff. It implies 
that the probability of finding very high values decreases sharply. 
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of networks and distributions [22]. Both the distributions (of &6, &7) are governed by power laws in 
the bipartite drug-target network. Hence, in the drug network, the first and second neighbors of a 
randomly chosen drug- H@, HF respectively, are given by (see derivation in Appendix 1.1) 
H@ = >):(@ ?
( @=:A
>): ?( @=:A IJK
JL>)B(F ?( @=BA − >)B(@ ?( @=BA
>)B(@ ?( @=BA MJN
JO                      2.3 
 
HF
= >):(@ ?(
@=:A
>): ?( @=:A PQ
R>):(F ?( @=:A − >):(@ ?( @=:A>):(@ ?( @=:A ST
U
PQ
R>)B(F ?( @=BA − >)B(@ ?( @=BA>)B(@ ?( @=BA ST
UF            2.4. 
 
 
Fig. 2.1 Probability distribution of targets per drug (&6) on log-log plot. The straight line approximates power-
law exponent *@ ≈ 1.75 ± 0.09 . *@  and scale parameter E@  are obtained by regression Eq. (2.2a) on a 
logarithmic scale, the exponential cutoff (@/=: ≈ 0.97. 
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Fig. 2.2 Probability distribution of drugs per target (&7) on logarithmic plot. The straight line approximates 
power-law exponent *F ≈ 1.9 ± 0.1. *F  and scale parameter EF  are obtained by regression of Eq.(2.2b), the 
exponential cutoff (@/=B ≈ 0.98. 
I find by substituting the parameters, H@ ≈ 34, HF ≈ 3148.5. Therefore, the path length [22] for the 
drug network is  = log \ ]^:_ /log \^B^:_= 1.76. The low path length is not surprising given the presence 
of drugs possessing many targets and it could point to a lower diversity in the activity profiles of many 
drugs. Note that the computed values are highly sensitive to decimal place considerations of the cutoff 
parameter and power law exponents. However, the computed values match with those observed within 
a range. 
Further, I approximate the probability distribution of the numbers of co-drugs, that is, the number of 
drugs that are connected through sharing a common protein as an active target. It is given in Eq.(2.5) 
as the probability that a drug has k links in the (co)drug network, 
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; ≈
>):(@ PQ
R 1>)B(@ ?( @=BAST
U `>)B(@ ?( @=BAa & + 1@()B
>): ?( @=:A                          2.5. 
This is based on some approximations considered for mathematical convenience (a sketch of the 
derivation is provided in Appendix 1.2). In order to see how it deviates from the observed degree 
distribution of the network of drugs constructed from the data, we plot the two distributions in Fig.2.3. 
This calculation is helpful because the actual distribution does not show a perfect power law behavior. 
The adjacency matrix of this graph of co-drugs is c′"# = 1 if drugs i, j are commonly active on at least 
1 protein and c′"# = 0 if the activity profiles of i, j have no commonalities. We impose the range of 
observed connectivity to get a normalized predicted probability. Fig.2.4 compares the cumulative 
distribution functions of distributions shown in Fig.2.3. The figures and Kolmogorov-Smirnov test 
statistic confirm the correspondence between observation and the prediction in Eq.(2.5). It is 
interesting to see a power law connectivity distribution of drugs as it suggests the greater diversity 
shown by some drugs (as compared to others) that they are active on many different proteins.  
 
2.3 Chemical Similarity of Co-drugs 
According to the similarity principle, chemically similar drugs tend to act similarly on the proteins. 
The connections between drugs can be categorized in two dimensions. These correspond to the 
structure and activity attributes of interactions. One of them is the pairwise chemical similarity 
indicated by the weighted adjacency matrix C and the other is the activity similarity. In this chapter, I 
consider activity similarity as a binary attribute, implying whether (1) or not (0) a pair of drugs has a 
target in common. It determines the connections in co-drugs network. In line with the similarity 
principle, a drug sharing high chemical similarity with a high number of drugs should have a high 
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number of co-drugs. However, it is known that the presence of activity cliffs in the pharmacological 
space contradicts this behavior. It is therefore important to investigate the extent to which the 
similarity principle is valid in the given data. When chemically similar drugs do not share any targets, 
the interactions would be highly distinctive. 
 
Fig. 2.3 Comparison of observed and computed probability distributions of connectivity or the number of co-
drugs.   
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Fig.2.4 Comparison of observed and computed cumulative probabilities of connectivity or the number of co-
drugs. Cumulative probability is plotted with number of co-drugs. Kolmogorov Smirnov test statistic using 
cumulative distribution functions Fn, F is D=sup|Fn-F|=0.17 which is significant at 0.05 level. Hence the 
correspondence between observed and computed probabilities is statistically significant. 
 
In this co-drug network, the average chemical similarity observed between drug neighbors is 0.12. 
This is not high as expected from the similarity principle. Fig.2.5 indicates this, and how majority of 
neighbors share lower chemical similarity than higher. It means that the links between co-drugs 
(possessing a common target) may not possess a very high chemical similarity.  
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Fig. 2.5 (Top) Average chemical similarity of the links in the neighborhood of a drug. (Bottom) Variation of the 
number of neighbors or co-drugs with chemical similarity below a threshold d , with d. 
 
Why is this and how does the deviation become important for identifying distinctiveness? In 
particular, what is the probability that a drug has chemically similar co-drugs? Chemically similar co-
drugs are those pairs of connected drugs that share chemical similarity (c) at least as high as c =0.3. 
For studying distinctiveness, it is helpful to investigate the typical distribution of chemical similarities 
in the neighborhood of drugs. For instance, according to the similarity principle, two chemically 
similar drugs should have many targets in common. If a drug shares a target with many others, is it 
necessarily similar in its structure to theirs? The number of drugs in the neighborhood of a drug and 
the distribution of those drug links in levels of chemical similarity becomes important for 
distinguishing distinctive drug interactions from non-distinctive ones. 
 
It is known that the probability that a link points to a vertex with degree k is proportional to &; and 
[22] the average connectivity of the drug network is 〈&〉 = ∑ &;  ; . Further, every link must possess c 
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in one of the n categories in the range (chemical similarity " =  hi0, 1j for all i =1,2..n). The 
probability of finding links in category  = " is given by " and is obtained from the data. If G" is 
the number of links in this category, then the probability that a drug having k co-drugs will have its 
links distributed into the bins of chemical similarity would be proportional to 
; &!G@! GF! … . Gm! @n:FnB … . mno                           2.6 
 
where ∑ " = 1, ∑ G"m"q@" = & , considering k links to be independent trials. This way, the links 
around a drug would be distributed in the various categories of chemical similarity in accordance with 
the multinomial distribution. In this network, 〈&〉  is the average connectivity, so the expected 
frequency of links in dr  category of chemical similarity is given by 〈&〉" . The variance is 〈&〉"1 − ", and the average chemical similarity in the neighborhood of a drug is ∑ "G"/m"q@〈&〉. Here, for the drug network, 〈&〉 = 38.24, the variation of 〈&〉" is shown in Fig. 2.6 for n=19 
categories @h  [0, 0.05], Fh  [0.05, 0.1], sh  [0.1, 0.15]….  @th  [0.95, 1]. The sharp drop in the 
expected frequency as " increases is attributed to the disproportionately high number of links having c 
< 0.3. These links are not of pharmacological significance yet they form 99.7-99.8% of the links. 
These are considered redundant in pharmacology and we ignore these in future. 
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Fig.2.6 Variation of average frequency of links in the categories of chemical similarity in the interval [0,1] 
divided in subintervals of 0.05 width. 
 
Considering that 〈&〉 links with co-drugs are independent, these links may be distributed in different 
categories of c, ranging from low to high. The resulting distribution can be approximated as a 
multinomial. I assign the number of links in these intervals of c and as before, compute the 
probabilities G"/〈&〉 . The probability mass function (pmf) of the multinomial distribution can be 
computed. It would be relevant for distinctiveness to study whether or not the combinations favoring 
the categories of higher chemical similarities are probable. The most probable combination of number 
of links assigned to all n categories corresponds to the one with maximum entropy [24,25]. In other 
words, the most probable combination is the one with maximum multiplicity u = 〈;〉!n:!nB!….no! .  
I perform two experiments. First, I randomly assign each of the 〈&〉 = 39 links to one of the n=3 
categories of chemical similarities in the ranges [0-0.3], [0.3-0.6], [0.6-1] with equal probability of 1/3 
for each category. In 100 random samples, I find the combination of G" which maximizes M. This 
happens for G"h  [12, 13, 14] and any of the permutations. Considering the middle values of all 
subintervals or categories as their representatives of c, the average chemical similarity in the 
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neighborhood of a drug is around 0.46. The probabilities observed for finding links in these categories 
are given as "=[0.998, 0.0018, 0.0002], respectively. This means that @=0.998, F=0.0018, s=0.0002. Again, considering the midpoint representatives of c in the categories, the expected 
chemical similarity = 0.15 × 0.998 + 0.45 × 0.0018 + 0.75 × 0.0002 ≈ 0.1507. This is much lower 
than in the previous case. The difference is because of the large proportion of chemically redundant 
links that may dominate the neighborhood of a drug. Therefore, the high c categories are highly under-
represented in the drug neighborhoods.   
In the next experiment, I consider the links with chemical similarity at least 0.25 and ignore all the 
redundant links that the co-drugs may have. In doing so, a new drug network is constructed in which 
the interactions between two drugs are two dimensional as the linkages are formed by considering two 
independent properties. These linkages between two medicines are characterized as the pairs of 
medicines with c at least as high as 0.25 and one or more common targets. I refer to the network 
formed by these special interactions as the co-star network of drugs. The average connectivity of the 
network is 〈&〉 ≈ 4. The proportion of links retained is only 0.3%. The categorization of " considered 
is in intervals [0.25-0.5], [0.5-0.75], [0.75-1], midpoints of the intervals being representatives [25]. 
The observed probabilities of finding co-star links in these intervals are given as "=[0.8489, 0.132, 
0.0191]. The average chemical similarity of the configuration expected around a vertex or in the 
network is 0.375 × 0.8489 + 0.625 × 0.132 + 0.775 × 0.0191 ≈ 0.47. Now assigning  & = 4  links 
randomly 200 times to the categories with the observed probability scheme, the configuration of 
maximum M is G" = (1, 2, 1) or (2, 1, 1) or (1, 1, 2). Table 2 gives the results. The average chemical 
similarity around a vertex in the co-star network corresponding to maximum entropy configuration is 
around 0.625.  
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Table 1 Taking equal probabilities of the categories (1/3) and <k>=39 vw, vx, vy M Average chemical similarity 
 ∑ z{ × v{/y|y{qw  
(12,13,14) and its 
permutations 
7.84 × 10@} (maximum) 0.46 
(15, 12, 12) and its 
permutations 
6.8 × 10@} 0.458 
 
Table 2 Probabilities of the categories [0.8489, 0.132, 0.019] and k links, for maximum M 
k (vw, vx, vy Average chemical similarity 
 ∑ z{ × v{/~y{qw  
4 (1, 2, 1) and the permutations 0.625 
10 (5, 4, 1) or (6, 2, 2) 0.51 
15 (10, 3, 2) or (7, 7, 1)  0.49 
20 (9, 9, 2) or (13, 5, 2) or (12, 7, 
1) 
0.5 
 
 
The co-star network predicts average chemical similarity around a vertex that is closer (than the 
previous case) to that of the most probable configuration obtained by simulation, more so, as k is 
increased. This is interesting because the observed probability for interval of lowest c is still very high 
as compared to intervals of high c. Thus co-star network can reveal distinctive interactions between 
medicines as it is constructed using two criteria for formation of links- activity similarity and chemical 
similarity. Further, after removal of redundant links, the linkages of co-star network become 
perceptible for comparison across various classes or intervals of chemical similarities. The connections 
of individual vertices with higher connectivity than average would be dominated by relatively lower 
than higher chemical similarities. The multinomial distribution puts greater mass (pmf) on 
combinations favoring lower c. From Eq.(2.5) the probability of finding drugs with high connectivity 
diminishes as power law. So, from Eq.(2.6), as the connectivity (or functional similarity) of a drug 
increases, its links tend to be less restricted to the low c domain. Equivalently, the preponderance 
increases in intervals of higher c. This is a plausible explanation for the results in table 2. That being 
said, it is interesting that the most probable average c in the neighborhoods of highly connected drugs 
decreases and is closer to the expected value. 
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This network can help in identification of distinctiveness at various levels of non-redundancy. This 
means changing the minimum c criterion to construct the network can reveal the various ways in 
which chemical similarity may be distributed among the links around a vertex. Increasing minimum c 
reveals the extent to which the compliance with similarity principle would increase but this is not 
always feasible because there is a limit on the range of c that can be considered as redundant. The 
above analysis is clearly not in accordance with the similarity principle and distinctiveness emerges 
from this re-analysis of the information.  
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Chapter 3 
 
DISTINCTIVE INTERACTIONS: A QUANTITATIVELY REASONED 
PERCEPTION 
 
 
The drug network constructed from the drug target data in Chapter 2 showed that drugs sharing 
activities were quite chemically similar to each other but the average c in the neighborhoods of drugs 
was not high. This means that there is a large number of drugs sharing activities but the chemical 
similarity of these drug pairs is not high. Therefore, one can find a lot of pairs with low or 
intermediate c having at least one common target. As we have seen in the last chapter, as the number 
of connections of vertices in the drug network increases, the links may not be restricted to the low c 
range, but the average c (of the most probable configuration) in the drug neighborhoods would 
decrease. This indicates a tradeoff between increase in similar activity and the average c. For assessing 
the compliance with the similarity principle, however, it is more useful to enumerate the activity 
similarity by number of common targets. This method would give the level of activity similarity of a 
pair and help in discerning the pairs that are highly similar in activity at any level of c>0.3. Such pairs 
at high levels of c can be accurately classified as non-distinctive in nature.   
Activity cliffs in the pharmacological landscape are indicated by discontinuities in structure activity 
association. These type of cliff interactions are formed by pairs of drugs having high c and highly 
divergent activity profiles, meaning, the drugs have vastly different activities on the same proteins. 
They are represented by distinctive drops in similar activity along the chemical space in the landscape. 
The extent of their non-compliance with the similarity principle (or as I refer to these aberrations as 
their distinctiveness) is quantified by measuring the dissimilar activity of the drugs in these pairs 
[13,17]. Previous studies have focused on dissimilarity and similarity in activity profiles of drugs as 
complementary measures. Measures like sali are constructed using pairwise differences in activity 
values and the chemical similarity of drugs [17]. These are studied as pairwise weights in a weighted 
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adjacency matrix of all the drugs from which cliff-like pairs are identified as the ones showing high c 
and high dissimilarity in activity. However, these kinds of measures are threshold dependent and not 
well defined as I discuss later in this chapter.  
In this chapter, I specify an interaction between two drugs quantitatively using two measures of 
activity (i) dissimilarity or variation (d) and (ii) similarity (s) in activity profiles. For drugs, the 
measures do not add to 1596 necessarily, in fact  ≠ 1596 − . The measurements are made using the 
activity information of 1354 drugs on 1596 proteins in A (described in section 2.1). Distinctive 
interactions are defined in two ways in terms of these two measures. Interactions are distinctive if the 
pairs of drugs either have high c and high d, or have high c and low s. I use chemical similarity data as 
mentioned above. Pairwise measures of c, s, d are weights of the interactions and can be represented as 
elements of a weighted adjacency matrix. Using this representation, I try to compare the network 
characteristics in terms of c, s, d. This is relevant for understanding distinctiveness because it helps us 
to find correspondence between clusters of chemically similar drugs and those of drugs having similar 
or dissimilar activity. In particular, which drugs in the network have high c and which have high s, 
high d? Is there a difference?  
Fig. 3.1 shows the difference in the spectral properties of C and the weighted network obtained by 
random assignment of weights in the adjacency matrix, , averaged a 100 times. The weights of  
are randomly chosen in the range [0,1]. The eigenvalue distribution of  is quite different from that of 
C. This quantified by the spectral distance [26, 27], which computes the difference between the 
eigenvalues as in Eq. (3.1). If " , ", i=1,2,..N are eigenvalues of C,  respectively, then spectral 
distance is 
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Fig. 3.1 Histogram of eigenvalues of C (left) and of the random version of C (right). 
 
 = " − "F]"q@                                     3.1. 
It is as high as 21454. Drug Lithium shares least chemical similarity with others in the network.  
 
 
3.1 Network Modifications and Distinctiveness 
I first compare the networks using the unweighted versions of networks C, Ψ,  for N=1354 drugs. 
The unweighted versions are given by  ×  adjacency matrices as (i) "# = 1  if the chemical 
similarity of medicines i,j is at least as high as a constant (const), and 0 otherwise (ii) Ψ"# = 1 if the 
medicines i,j are commonly active on at least 1 protein, and 0 otherwise (iii) ζ"# = 1 if the activities of 
medicines i,j are variant on at least 1 protein, and 0 otherwise. Ψ"#   is the co-drugs network of Chapter 
2 [27]. We also refer to Ψ,  as co-similar and co-variant networks respectively. Clearly,  is a denser 
network than Ψ because it is more likely to find drugs that act dissimilarly on at least one protein. We 
will see this affects the interpretation of distinctiveness. Note that const specifies the threshold of 
chemical similarity for a link to be considered as viable. This specification affects the number of 
connections in all the networks (if we consider the similarities and dissimilarities in functionalities of 
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pairs of drugs (ij) for which "# = 1). A quantity studied is the sparsity of the network, which is 
defined as the ratio of number of links observed ("m;) to the total number of links. Sparsity= "m;/B. Fig. 3.2 depicts the decrease in the number of links as const increases, the networks becomes less 
dense.  
Weighted versions of these network measures consider the magnitudes of similar and variant activity 
between medicines. C represents the weighted adjacency matrix of chemical similarity.  If Ai and Aj 
are activity profiles of drugs i,j, that is the proteins k for which Ai(k) =1 and Aj(k) =1, then Ψ"# =
c"; ∩ c#;. Here Ψ has weighted adjacency matrix for N=1354 drugs. We denote the similarity 
weights or magnitudes as s. The commonly unresponsive proteins are ignored. Every element of the 
matrix denotes the weight of the link or the interaction between pairs of drugs. 
Variation between the activity profiles of two drugs measures the number of differences or the 
dissimilarity between their binary attributes, that is the number of proteins on which they differ in 
activity. The weighted network of pairwise variation of drugs are given by  ×  weighted adjacency 
matrix "# = |8c"; ∩ c;9 ∪ 8c; ∩ c#;9|. This is not the complement of Ψ as we ignore the 
commonly unresponsive proteins on all pairs of drugs while computing Ψ. Both these measures [27] 
are constructed along the lines of Jaccard coefficient without normalization. The constructions of Ψ 
and   are crucial for understanding distinctiveness because if their magnitudes and variances are 
distinct, one can compare the actual numbers of similar and variant activities. 
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Fig. 3.2 (Top) Sparsity plotted with the constant of chemical similarity. (Bottom) The decrease in 
average connectivity of the unweighted networks  (chem sim), Ψ  (activity sim), ζ  (activity 
variation). The horizontal axis in both figures shows const as chem sim threshold. 
 
 
3.2 Spectral properties of C, ,  
This section analyzes the spectral properties of the unweighted and weighted adjacency matrices of 
chemical similarity, activity similarity and activity variation of the medicines. Particularly, we focus 
on the eigenvalues of the  ×   Laplacian matrix (L).  
> =  −                          3.2. 
Here D is the  ×  diagonal matrix with entries "" = ∑ "#]#q@  . The matrix X is considered as the 
observed (weighted and unweighted) adjacency matrices for , Ψ, .  L is defined for each of the 
measures as > , >, >  respectively and for the unweighted measures as >, > , > respectively. The 
eigenvalues of L are 0 = @ ≤ F ≤ s … . . ≤ ]. The smallest eigenvalue of L is 0 and the second 
smallest non-zero eigenvalue of L is called the Fiedler value, which gives the algebraic connectivity of 
the network. Its lower bound is inversely proportional to the diameter of the network and the 
eigenvector corresponding to this eigenvalue, the Fiedler vector, gives the spectral bisection of the 
network, as a community structure. It is the structure obtained such that the vertices in a group are 
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more connected (or tightly connected for weighted networks) to each other than to vertices belonging 
to another group. Figs. 3.3-3.5 show the community structure given by Fiedler vector of > 
constructed using const=0.3, 0.45, 0.65. In all these bisections, there is little difference between 
weights of links within groups and those across groups. The nature of drugs constituting the 
communities changes drastically as const increases. This may happen because the relative chemical 
similarity of drugs in the network changes on an average as some interactions of c<const are ignored. 
In Fig.3.3, the bisection is not perfect, the structure of the pair (Teniposide, Doxorubicin) is maximally 
similar (=1) and becomes prominent in the absence of a large number of links of intermediate c. Both 
these drugs affect DNA synthesis, structure but have different therapeutic functionalities.  
 
 
 
Fig. 3.3 Community structure of  with  = 0.3. The links gives the weight or chemical similarity between 
medicines within the two groups. For clarity the chemical similarities between medicines across the groups are 
not indicated. These drugs are: group 1 (top panel) –(Trospium, Oxyphenonium, Oxyphencyclimine, Clidinium, 
Glycopyrrolate, Oxybutynin, Tiotropium, Mepenzolate, Aclidinium)  and group 2 (bottom panel)-(Benzatropin, 
Cetrizin, Buclizine, Hydroxyzine, Cinnarizine, Meclizine, Diphenylpyraline, Cyclizine, Almitrine, Flunarizine). 
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Fig. 3.4 Community structure of  with  = 0.45. The links indicate their weights or chemical similarity 
within the two groups. For clarity, the pairwise chemical similarities across the groups are not indicated. These 
drugs are: group 1 (top panel) –(Ceftazidime, Cefalotin, Cefotaximine, Cefdinir, Cephalexin, Cefixime, 
Cephaloglycin, Cefaclor, Cefditorin, Cefuroxime, Cefapirine, Cefadroxil, Cefaprozil, Ceftriaxone, Ceftizoxime, 
Cefradine, Cefepime, Cefacetrile, Ceftibuten, Cefpodoxime)  and group 2 (bottom panel)- (Cefotiam, 
Cefamandole, Cefomicid, Cefoperazone, Ceforanide, Cefpiramide). 
 
Fig. 3.5 Community structure of   with  = 0.65. The links are shown with their chemical similarity 
weights within the two groups. High weight interactions within group are (Teniposide, Doxorubicin) and those 
across the groups are (Doxorubicin, Idarubicin), (Teniposide, Idarubicin), (Rescinnamine, Deserpidine). 
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In all cases shown in this chapter, the Fiedler vector contributions of majority of vertices are 
negligible. Hence, for the identification of community structure, we consider the vertices within a 
group as those whose components have the same sign and magnitudes at least as large as the standard 
deviation of the Fiedler vector components. Figs. 3.6-3.7 show the interactions filtered through a 
spectral bisection of ,  and the variation of community structure. The medicinal groups obtained 
for  in Fig.3.4 and for  in Fig.3.7 overlap to some extent. It is not surprising that the co-variant 
medicines appear in different groups of co-similarity.  
 
 
 
 
 Fig. 3.6 Network of interactions of  obtained by spectral bisection for  = 0.3. Connections between all 
medicines in the groups are shown. The drugs are: group1- (Lorazepam, Clobazm, Diazepam, Estazolam) and 
group2- (Temazepam, Alprazolam, Adinazolam, Clorazepate, Midazolam, Flurazepam, Halazepam, Triazolam, 
Flunitrazepam, Fludiazepam, Prazepam, Quazepam, Cinolazepam). 
 
It is important to observe that groups shown in Fig.3.7 consist of covariant medicines affecting 
ailments of central nervous system that are structurally quite similar. The difference in their activities 
is at a finer level of specification within the class of nervous system disorders. Also, not all medicinal 
pairs across the two groups are highly co-similar in activity. Therefore the groups represent medicines 
of nervous system with a common benzodiazepine structure but having fine distinctions in their 
Variation in activity, unweighted, for c>=0.3
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activity, which explains they are covariant on at least one protein. Weighted network analysis is 
required to infer how co-variant they may be. 
 
Fig. 3.7 Network of interactions of  obtained by spectral bisection for  = 0.45. Connections between all 
medicines in the groups are shown. The drugs are: group1-(Cefmenoxime, Ceftazidime, Ceftizoxime, Cefepime, 
Cefecetrile, Ceftibuten, Cefpodoxime) and group2-(Cefalotin, Cefotaximine, Cefditorin, Cefapirin, Ceftriaxone). 
 
The correspondence between d and c of medicinal pairs is further confirmed by computing the spectral 
distance in Eq. (3.1) between the distributions of eigenvalues of L for all 3 pairs of measures. Fig.3.8 
gives the impact of changing chemical similarity threshold const on spectral distance. It is not 
surprising that  is high for , ) given the difference in the construction of these measures. It 
decreases with increase in const because the average connectivity in  decreases. It is interesting that 
while  decreases for all 3 pairs (Fig. 3.8), it is the least for ,  at all levels of const. This may 
imply that the imposition of the threshold affects the overall connectivity (and structure) in both 
adjacency matrices equally. However, the change in const may make  a lot sparser. The magnitude 
of the largest eigenvalue decreases due to this perturbation and would be proportional to the 
probability of links having c≥const. This is shown in Theorem in Appendix 2. It highlights the 
difference between the correspondences of behaviors of structural similarity with those of activity 
similarity and activity variation. Such a quantitative reasoning is crucial for identification of what can 
be referred to as distinctive interactions, which we also see in detail later. The algebraic connectivity 
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Similarity in activity, unweighted, c>=0.45
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of the graphs increases with const indicating a decrease in diameter. It must be mentioned that the 
Fiedler value in this case may not be accurately observed because the gap between eigenvalues is very 
low and smallest non-zero eigenvalue of the Laplacian may be chosen quite arbitrarily. 
 
Fig. 3.8 Variation of spectral distance with const for , , , , ,   indicated by -*-, -o-, -.- 
respectively. The spectral distances of ,  and ( , ) are divided by 100.  
 
 
3.3 How Distinctive and How Probable? 
In this section, I extend the analysis of distribution of links in the co-star drug network of the previous 
chapter to study the distribution of distinctive links of a drug. Distinctiveness of an interaction is 
quantified in terms of the (i) magnitudes of chemical similarity and similar activity (s) exhibited by the 
pair of drugs, and (ii) magnitudes of chemical similarity and dissimilar or variant activity (d) of the 
pair (d is also referred to as variation sometimes). Intuitively, these two measures appear to be 
complementary but they give rise to very different conclusions on identification of distinctive 
interactions, as shown later. These measures allow a quantitative specification for identification of 
distinctive interactions by imposing (i) minimum level of c and maximum level of s for (c, s) 
specification, and (ii) minimum levels of c and d for (c, d) specification. A distinctive interaction is 
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typically one characterized by high c but low s. It can also be the one characterized by high c and high 
d. Therefore, the levels of c, s and d specify how distinctive an interaction is. 
Further, the probability of finding distinctiveness interactions would depend on the probability 
distributions of the levels of c, s, d observed. If we only consider the value of const used for the 
construction of the unweighted networks, we would have no information on the level of distinctiveness 
that is present in the drug network. The co-similarity network Ψ  contains information on the 
magnitude of similar activities between drugs and the co-variant network  contains information on 
the magnitude of dissimilar or variant activities between drugs. If a drug has k co-similar drugs, then 
these k links may be distributed in categories of c and s simultaneously. The magnitude of 
distinctiveness around such a drug (in accordance with the multinomial pmf as used in section 2.3) is 
proportional to  
; ;!n:!nB!….no! @, @n:@, FnB … @, nF, @n: … . . mno              3.3                         
 
where ∑ ∑ "#q@ ,m"q@ # = 1, ∑ Gmq@ = &. The structural and functional similarities are divided into 
n and m categories respectively and the links are distributed in a total of nm categories of c and s 
jointly. If a drug has k co-variant drugs, then these k links may be distributed in categories of c and d 
simultaneously. The magnitude of distinctiveness around such a drug is proportional to  
 
′; ;!n:!nB!….no! @, @n:@, FnB … @, nF, @n: … . . mno              3.4                         
 
where ∑ ∑ "#q@ ,m"q@ # = 1, ∑ Gmq@ = & . ′; is the probability of having k covariant drugs. The 
structural similarity and functional dissimilarity are divided into n and m categories respectively and 
the links are distributed in a total of nm categories of c and d jointly.  
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Considering n=m=3 results in nm=9 categories of joint (c, s) with " in the ranges [0.25-0.5], [0.5-
0.75], [0.75-1] and # in the ranges [0-8], [9-17], [18-28]. The 3 representative midpoints of these 
ranges are @ = 0.375, F = 0.625, s = 0.875 and @ = 4, F = 13, s = 23. 
The joint probabilities of finding links in 9 categories 8" ∩ #9  of 
[@, @j, i@, Fj, i@, sj, iF, @j, iF, Fj, iF, sj, is, @j, is, Fj, is, sj are observed as 
 [0.8169, 0.0292, 0.0028, 0.1264, 0.0053, 0.0004, 0.019, 0, 0] respectively. The average 
distinctiveness is ∑ "#" , #",# . Assuming structural and functional similarity as independent 
attributes of a drug interaction, 8" , #9 = "#. I repeat the experiment of assigning & links to 
the 9 categories. The average distinctiveness calculated is 1.823. The probability of link in the first 
category of lowest c and s is the highest, and for any level of c, the probability decreases as s 
increases. While the multinomial distribution puts greatest mass on lowest category, Fig. 3.9 shows a 
relative reduction in its contribution to average (non) distinctiveness.  
 
Fig. 3.9 Pie chart for probabilities of categories [c, s] (left) and their contributions to (non) distinctiveness 
(right). The blue region represents the lowest [c,s] category. 
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Therefore, even after removing the redundant links (of c<0.25), the similarity principle is contradicted, 
as the probability is 0 in the last two categories. This is confirmed by simulations as most links are 
assigned to [@, @j or [F, @j. Also, if the connectivity of a drug increases, the average distinctiveness 
of the most probable configurations remains close to the expected average (non) distinctiveness. Table 
3. (Note they are still different). It implies that when the number of co-similar links increases, the links 
tend to be distributed in more categories than just the first, spanning the categories of high c and high 
s. This indicates increase in non-distinctiveness. Fig. 3.10 shows the changes in observed distribution 
of links from expected. In the experiment of random assignment of links using the expected 
probabilities, the difference between contribution of [@, @j and the other categories is highly reduced. 
Note that expected probabilities refer to the observed probability scheme used for the simulation. 
 
 
Table 3 Configurations and distinctiveness of the most probable configurations using c, s 
k (vw, vx, vy, v , v¡, v¢, v£, v¤, v| Average (non) 
distinctiveness 
 ∑ "#" , #",#  
4 (2,0,0,1,0,0,1,0,0) or 
(2,1,0,0,1,0,0,0,0) or 
(2,1,0,1,0,0,0,0,0) 
1.596 
10 (5,1,0,3,0,0,1,0,0) or 
(5,1,0,2,1,0,1,0,0) 
2.5 
15 (8,1,0,5,0,0,1,0,0) or 
(8,0,0,5,1,0,1,0,0) 
2.41 
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Fig.3.10 (Top left) The expected probabilities of categories [c, s] based on observations. The rest of the pie 
charts give the probabilities of categories obtained by observations in table 3 for the experiment k=4, 10, 15.  
 
If in the neighborhood of a drug, the probability of finding connections of high c and high s is large, 
then neighborhood is non distinctive. If probability of high c and low s is high, then the interactions 
are distinctive. Intermediate ranges are inconclusive and can be classified as either distinctive or non-
distinctive.  
Similarly, the analysis can be repeated by considering d instead of s. For the same ranges of c, the 3 
ranges # of interactions indicating the magnitude of covariance (d) between activities of drugs (from 
the covariant network, .  
The ranges are [0-37], [38-75], [76-114], and the midpoint values representative of these ranges are 
@ = 18.5, F = 56.5, s = 95  respectively. The probabilities of the 9 categories 8" ∩ #9  of 
[@, @j, i@, Fj, i@, sj, iF, @j, iF, Fj, iF, sj, is, @j, is, Fj, is, sj  are observed as 
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 [0.843, 0.0035, 0.0025, 0.1317, 0.0003, 0, 0.019, 0, 0] respectively. The average distinctiveness is 
∑ "#" , #",# . I repeat the experiment of assigning &  links to the 9 categories. The average 
distinctiveness calculated is as high as 7.85. It is higher than obtained by using s because the 
magnitudes of d are higher. From the observed probability scheme, we can say that highly distinctive 
interactions are rarer (upper categories), but distinctive interactions are prevalent as indicated by the 
high probability concentrated in the first two categories and [s, @j. It is important to investigate their 
nature. It is also striking from results in Table 4, that the average distinctiveness of the most probable 
configurations obtained for various levels of connectivity, k in  is somewhat higher than the expected. 
Again, expected probabilities are those computed using observations. This may mean a bias toward the 
first categories or that observed numbers in first categories must be higher. While the multinomial 
probability puts greatest mass on lowest category, Fig.3.11 shows a relative reduction in its 
contribution to average distinctiveness. It implies that when the number of co-variant links increases, 
the links tend to be distributed in more categories than just the first, spanning the space including 
categories of high c and high d (increase in overall distinctiveness). This can be seen from Fig. 3.12 
showing the changes in observed probability distribution of links from expected. 
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Fig.3.11 Pie chart for probabilities of categories [c,d] (left) and their contributions to distinctiveness (right). 
The blue region represents the lowest [c,d] category. 
 
 
Table 4 Configurations and distinctiveness of the most probable configurations using c, d 
k (vw, vx, vy, v , v¡, v¢, v£, v¤, v| Average distinctiveness 
 ∑ "#" , #",#  
7 (3,0,0,3,0,0,1,0,0) or 
(4,0,1,1,0,0,1,0,0)or 
(3,1,0,2,0,0,1,0,0) 
11.63 
10 (5,1,0,3,0,0,1,0,0) or 
(6,0,0,3,0,0,1,0,0) or 
(5,0,0,3,0,0,2,0,0) 
10.03 
15 (9,0,0,4,0,0,2,0,0) or 
(9,0,0,5,0,0,1,0,0) 
or(10,0,2,3,0,0,0,0,0) 
10.06 
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Fig.3.12 (Top left) The expected probabilities of categories [c,d]. The rest of the pie charts give the probabilities 
of categories obtained by observations in table 4 for the experiment with k=7, 10, 15. 
 
 
It is interesting to note that if the probability of high c and high d is large, then the neighborhood6 is 
highly distinctive, but if probability of high c and low d is high, then the interactions are considered 
distinctive. This is the major difference that the application of measures s and d can make on the 
interpretation of distinctiveness. It arises from the fact that while computation of s from weighted 
network  is proportional to Jaccard index (as is d from weighted network ), there is a number of 
proteins that pairs of drugs are inactive on in the data. (Indeed there are drugs that are not active on 
any of the proteins). These are ignored in the calculation of s, and so the drop in similar activity is not 
necessarily indicative of the rise in d. However, a huge rise in s does guarantee a drop in d. Therefore, 
                                                        
6 These experiments help to establish the inherent (increase in) uncertainty (or high information content) of the 
link attributes (c, s) and (c, d) actually found in the neighborhood of a drug (most probable configuration). It 
shows the possibility of high levels of distinctiveness and non-distinctiveness of links. 
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this analysis suggests that for distinctiveness, activity variation may be a more suitable measure to 
study than activity similarity. It indicates distinctiveness at different levels in the data and is a more 
selective filter of the interactions. 
 
 
3.4 Identification of Distinctive and Non-distinctive Interactions 
3.41 Measures of z¥ and z¦ 
As seen from the ranges specified above for c, s, d that the weights of the links are in the ranges of 
@@ <  < mm and @@ <  < mm. I construct the weighted networks of these link weights cs 
and cd for all links having  ≥ 0.3. Fig. 3.13 gives the probability density of  and  on logarithmic 
and semi-logarithmic scales. For  , a power law probability is indicated while   shows fast 
exponential decrease initially with the very high values are equally probable.  
 
Fig. 3.13 Probability distribution of weights as (1)   on logarithmic plot with straight line regression 
coefficient −1.78 ± 0.13 and (2)  on semi-log plot with straight line regression coefficient −0.35 ± 0.01. 
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The observed ranges of these weights are 0 ≤  ≤ 13.3 and 0 ≤  ≤ 53.5. The mean and standard 
deviation of cs are given by 1 = 0.0068, ¨ = 0.0083  respectively and mean and standard 
deviation of cd are given by 17 = 0.0015, ¨7 = 0.0645 respectively. While high cs weights would 
correspond to high non-distinctiveness, high cd weights correspond to high distinctiveness. It must be 
clarified that here ‘high’ is meant as being above average and how high is indicated by the number of 
standard deviations above average.  It is interesting that the probability of finding links of weight cs 
decreases as we go above the mean that is  ≥ 1 +  ¨ (for n=0,1,2,..) as a power law (Fig.3.14, 
power law exponent =1.41). It falls off faster as n is increased beyond 49-50. The 19 highly non-
distinctive interactions observed at n=100 are given in Fig. 3.15. These represent links between 
medicines and their analogs (sharing high c) having similar functionalities on same diseases. However, 
the probability of finding links of weight cd decreases very slowly initially  (for low n) but as a power 
law for higher n, (Fig.3.16, exponent =2.87), indicating very high variance in cd). The 14 distinctive 
interactions filtered by considering n=85 are between medicines and their analogs (highly chemically 
similar) which cure ailments of a particular class or kind but which are variant in their functionalities 
(Fig.3.17). These may be studied further to know the nature of distinctiveness.  
Distinctive interactions occur between drugs of the same class, treating the same kinds of diseases but 
have finer distinctions in their therapeutics. The highly non-distinctive drug interactions are observed 
between drugs that are used commonly such as nutrients thus having same functionalities on diseases, 
proteins. Thus a hierarchical nature of link distribution across various levels of distinctiveness and 
non-distinctiveness is indicated by power law, but the interpretations of links in the uppermost 
categories of (largest n) both measures cs and cd are totally different. Finding distinctive interactions 
with cs measure (low cs) is not precise because we observe  ≤ 1  for 97% of the links. The 
networks in Figs. 3.15, 3.17 show clustering, which means that structurally similar compounds 
participate in many interactions. The power law dependence of probability is interesting as it indicates 
a hierarchical emergence of distinctiveness by relaxation of the evaluation criteria. It is also crucial to 
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note that the medicines constituting the interactions in Fig. 3.15 are also observed in Fig.3.6 which 
seems surprising because the metric applied in that analysis was d and not s. 
 
 
 
Fig. 3.14 (Top) Probability of finding links of weight  ≥ 1 +  ¨ with n (Bottom) Logarithmic plot of 
probability with the number of standard deviations, straight line in the tail has regression coefficient or power 
law exponent −1.41 ± 0.027.  
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Fig.3.15 Non distinctive interactions filtered using  ≥ 1 + 100 ¨. These are  
(Temazepam, Diazepam), (Temazepam, Oxazepam), (Amitriptyline, Notriptyline), (Amitriptyline, Doxepin), 
(Olanzapine, Clozapine), (Olanzapine, Loxapine), (Clozapine, Loxapine), (Loxapine, Amoxapine), (Imipramine, 
Desipramine), (Midazolam, Flurazepam), (Midazolam, Triazolam) Midazolam, Fludiazepam), (Flurazepam, 
Fludaazepam), (Flurazepam, Quazepam), (Risperidione, Fencamfamine), (Halazepam, Diazepam), Halazepam, 
Prazepam), (Diazepam, Fludiazepam), (Diazepam, Prazepam). 
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Fig.3.16 (Top) Probability of finding links of weight  ≥ 17 +  ¨7 with n (Bottom) Logarithmic plot of 
probability with the number of standard deviations, straight line in the tail has regression coefficient or power 
law exponent −2.87 ± 0.04. 
 
 
0 10 20 30 40 50 60 70 80 90 100
0
0.5
1
1.5
2
x 10
-3
Number of standard deviations above mean
P
ro
b
a
b
ili
ty
 o
f 
fi
n
d
in
g
 a
 l
in
k
10
0
10
1
10
2
10
-5
10
-4
10
-3
10
-2
Number of standard deviations above mean
P
ro
b
a
b
ili
ty
 o
f 
fi
n
d
in
g
 a
 l
in
k
 46 
 
Fig.3.17 Distinctive interactions filtered using  ≥ 17 + 85 ¨7 . These are (S-Adenosinmethionine, 
Adenosine Triphosphate), (L-Aspartic acid, Glycine), (L-Aspartic acid, L-Cysteine), (Adenosine monophosphate, 
Adenosine triphosphate), (Adenosine monophosphate, Flavin Adenine Dinucleotide), (Succinic acid, Glycine), 
(Riboflavin, Flavin Adenine Dinucleotide), (Adenosine triphosphate, Vidrabine), (Adenosine triphosphate, 
Adenosine), (Adenosine triphosphate, Fludrabine), (Adenosine triphosphate, Flavin Adenine Dinucleotide), 
(Vidrabine, Flavin Adenine Dinucleotide), (Adenosine, Flavin Adenine Dinucleotide), (Pseudoephedrine, 
Ephedrine). 
 
 
 
3.42  Structure Activity Landscape Index and z¦  
 
Researchers have struggled with appropriate quantification of activity cliffs. This is because qsar 
models are less effective when small structural changes in drugs result in large variation in their 
activity. They are known to require additional information from experiments to offer predictions of 
cliffs. Also, the quantitative methods developed cannot be used to filter out most distinctive links. The 
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most commonly used measure for activity cliffs is the -structure activity landscape index (sali) [17] as 
it combines the chemical similarity and activity variation of drugs. For two drugs i, j sali is given by 
"# = ©ª@(©ª . This measure is used to characterize the drug network with an adjacency matrix by 
placing the elements of the matrix as 1 (or connected) if sali is greater than a threshold or sali constant, 
and 0 otherwise. While sali puts more weight on activity variation between pairs that possess high 
chemical similarity, it is rather contentious. This is because the sali constant is not well defined [17]. 
And the mathematical basis is insufficient because in this integrated measurement, high scores may 
arise from very low c and high d. This does not help in analysis of distinctiveness, which strictly 
requires both high c and high d. Since this method of network analysis is dependent on choice of sali 
constant, it is important to know the probability distributions of weights of drug interactions. I apply 
this approach later for a better characterization of the pharmacological distinctiveness. 
The measure  considered above is an integrated method that accounts for c and d jointly. However, 
as seen earlier, unweighted network analysis is not useful because of the increasing sparseness with 
threshold. In the Laplacian constructed using sali adjacency matrices, a decrease in the algebraic 
connectivity is indicated as sali constant is increased (Fig.3.18). 
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Fig. 3.18 Variation of algebraic connectivity or the Fiedler value of sali Laplacian with sali constant.  
 
 
 
The inconclusiveness of this method for distinctiveness is indicated by the shift in the components of 
eigenvector corresponding to the Fiedler value as the sali constant is decreased. This makes it difficult 
to divide drugs into groups, as majority of links are either positive or negative in a very small range. 
Further, the maximum spectral gap is very large which rules out the existence of community structure. 
This leads us to classification of links as distinctive or non-distinctive based on whether or not their 
sali is greater than sali constant. Since there is a difference in the constructions of sali and  ×  = cd, 
the interpretations of distinctive and non-distinctive will differ and in fact there is no specification for 
non-distinctiveness given by sali. Thus sali is useful for filtering out the pairs of interactions that 
possess low structural similarity and very low variation in activity. The pairs scoring intermediately in 
these two dimensions of c and d are not properly classified. 
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3.43 Correlation Matrix Analysis 
This subsection checks the results of analysis of correlation matrix of drug activity with the similarity 
measure s introduced previously. The matrix of correlations between drug activity profiles is 
computed as the Pearson coefficient and −1 ≤ "# ≤ 1. A positive correlation indicates similar 
behavior of two drugs on same proteins but negative or anti-correlation means they act oppositely on 
the same proteins. Note that the coinciding 0 activity values in two binary activity profiles also 
contribute to correlation whereas these are ignored in calculating s. I compare the eigenvalues of the 
observed Cor with those of a random correlation matrix generated by randomly shuffling the activities 
of drugs on proteins (random shuffling of activity profiles of all drugs) and averaging over 100 
realizations. The comparison is made including all links in Fig. 3.19, keeping only the links whose  ≥
0.3 in Fig. 3.20 and only the links whose  ≥ 0.45 in Fig. 3.21. In the last two cases, the eigenvalues 
of the random matrix are smaller than the corresponding eigenvalues of observed Cor. Fig.3.22 shows 
a drop in largest eigenvalue «n with const.  
 
Fig. 3.19 Histogram of eigenvalues of correlation matrix: random (left) observed (right). 
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Fig.3.20 The eigenvalues   are plotted with probabilities %.  Comparing of eigenvalues of the random 
correlation matrix with those of the observed correlation matrix. Only the links wits  ≥ 0.3 are retained.  
 
 
Fig.3.21 The eigenvalues   are plotted with probabilities %.  Comparing of eigenvalues of the random 
correlation matrix with those of the observed correlation matrix. Only the links with  ≥ 0.45 are retained.  
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Fig.3.22 Largest eigenvalue of observed Cor retaining links with  ≥  plotted with const. 
 
 
These analyses reveal that Cor has a non random character but there is no significant information on 
distinctive or non-distinctive interactions. 
 
In this chapter, I have tried to identify distinctive pairs of drugs using two measures of activity, 
similarity and variation. Network analysis shows that drugs contributing highly to chemical similarity 
in the network are not the same as those contributing to s or d. This means that there may be ranges of 
these interaction attributes –c, s, d where distinctiveness and non-distinctiveness become perceptible. 
The distribution of links in various (joint) categories of (c, s) and (c, d) confirms the preponderance 
decreases in the upper ranges, however, for links at any level of s or d, in the range c>0.3, interactions 
can be classified as distinctive and non-distinctive. Not differentiating between these kinds of 
interactions can lead to errors in prescriptions and adverse health outcomes. Therefore, as this chapter 
has shown, the difference between s and d can have implications for accurate identification of 
distinctiveness at multiple levels. Further, the standard methods of sali and correlation analysis are 
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insufficient for investigating distinctiveness. Measuring distinctiveness using a combination of 
attributes, cs or cd yields distinctiveness at different levels. These findings motivate a probabilistic 
analysis of distinctiveness at various levels in different ranges of the chemical space. This is 
introduced in the next chapter. 
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Chapter 4 
 
TOWARD A CANYON CHARACTERIZATION OF THE ACTIVITY LANDSCAPE 
 
 
The structural features of a drug compound describe its physicochemical properties that determine its 
biological activity on protein targets [21]. A vast number of combinations or analogs that result from 
slight changes in chemical structure may not contribute to the diversity in biological activity or 
functionality of drugs. We saw in chapter 2 that the drug target behavior of this data shown in Figs. 
2.1, 2.2 resembled that previously established for different data. Few drugs are active on many more 
targets than average while a large number of drugs are active on much fewer targets [3,20]. This points 
to the discovery of certain molecular combinations having highly versatile functionalities. If targets 
are sufficiently distinct in their chemical nature, then the high druggability of few targets points to low 
specificity of a large number of medicines. Dissimilarity in activities of drugs when measured 
pairwise, often reveals pairs of drugs with highly dissimilar activity. Is variation in activity of drugs 
necessarily based on their chemical structures? In this chapter, I analyze in detail the structure activity 
association for the present data sample using the features of the activity landscape. The aim is to 
devise a quantitative characterization of the landscape for a precise identification and interpretation of 
the distinctive interactions.  
Medicinal chemistry has generally relied on the similarity principle [1,13,14]. However, many 
exceptions are known. Development of medicines and analogs with many targets facilitates the 
production of multipurpose medicines. It also leads to the emergence of activity cliffs [17,18], 
specifying pairs of structurally similar drugs having highly variant biological activities. These cliff-
like interactions between drugs correspond to extreme behaviors of pairs of chemically similar drugs 
showing unusually large deviations in activities. They are quantified by drops in similar activity of two 
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drugs. However, one may use the rise in pairwise variation of their activities instead. Distinctiveness 
can be measured as the either the drop in similar activity or rise in variant activity of two drugs. 
Activity landscape of drugs (or the pharmacological topography) is a two-dimensional space of 
chemical structure and functionality to which a pair of drugs can be mapped. Researchers have 
focused greatly on quantitative structure activity models to study the activity landscape. Nonetheless, 
the effectiveness of these models has been found to be inadequate when studying activity cliffs, that is 
when small structural variations result in large changes in biological activity [1,17,18]. In previous 
work, structure activity analysis has relied mainly on measures such as sali (discussed in detail in 3.42) 
and some algorithmic or statistical analysis [17,18]. We saw in the last chapter, these methods and 
specifications of distinctive drug interactions have limitations as they are threshold driven and 
descriptive. Moreover, increased activity variation may not indicate decrease in activity similarity 
particularly when the magnitude of similarity is determined by number of commonly active targets. 
Previous studies have not differentiated between these two measures of quantifying the aberrations. 
Further, the magnitude of data considered for the analysis can significantly change the patterns of drug 
activity on targets and the inferences on similar activity [19].  
This chapter provides a mathematical basis of the extreme deviations observed. It introduces a 
probabilistic analysis of the pharmacological topography and uses two measures of activity (similarity, 
s and variation, d) jointly with the corresponding chemical similarity c to investigate distinctiveness. It 
would facilitate identification of distinctive interactions on different scales of measurements. 
Probability distributions of s, d, c are used to identify medicinal categories involved in the highly 
distinctive interactions. I compute the predicted probabilities of s and d jointly with c. This gives the 
probability of distinctiveness at varying levels. The level of distinctiveness of a pair of drugs (or drug 
interaction) is specified according to the magnitudes of the attributes s, d, c for that pair. This chapter 
shows that the choice of the measurement (low s or high d) affects the interpretation of distinctiveness 
and the landscape. I use statistical logic based on established methods to argue that d is more efficient 
estimate than s for obtaining an optimal forecast (though neither of them can be used to construct a 
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statistically consistent estimate). In particular, the probabilistic analysis of distinctiveness using both 
measures induces a transition from cliffs to a new characterization of the landscape called activity 
canyons. 
 
 
4.1 Non Random ¬­, ­   
First, the spectral properties of drug network  are compared with those of a corresponding random 
network R. In this network , two drugs are connected if they have at least one target in common. A 
network generated by random shuffling of binary activities of drugs in the bipartite network results in 
a random network of drugs R. The random shuffling preserves the sizes of the activity profiles of 
drugs. Since we are interested in the analysis of drugs, we do not shuffle the protein response profiles. 
The adjacency and Laplacian matrix for the drug network is the same as described in section 3.1.  
shows non-random behavior as indicated in Fig. 4.1. In the exact same manner, Fig. 4.2 compares the 
eigenvalue distribution of the Laplacian of  with that of a corresponding random network R.  is 
also found to have a non-random behavior. 
 
 
Fig.4.1 Comparison of probability distribution of eigenvalues  of Laplacian of  >®  defined in the previous 
chapter Eq.(3.2) with that of a randomly generated adjacency matrix R, averaged on 25 realizations. The 
eigenvalues of R are much smaller than those of > .
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Fig. 4.2 Comparison of probability distribution of eigenvalues  of Laplacian of  > defined in the previous 
chapter Eq.(3.2) with that of a randomly generated adjacency matrix R, averaged on 25 realizations. The 
eigenvalues of R are much smaller than those of > .
 
4.2 Distinctiveness in the Landscape : The Canyon Representation 
Distinctiveness is the property of drugs having high structural similarity but varying activity profiles. 
An interaction between two drugs refers to the difference or similarity of activity of the drugs on the 
same protein. The discontinuities arising in the activity landscape due to sharp drops in similar activity 
along the chemical space represent drug interactions that are distinctive in nature [14,17,18]. They are 
not regular as they do not conform to the similarity principle. An interaction is distinctive when 
structurally similar drugs tend to behave oppositely on the same proteins. There may be two 
alternative specifications of a distinctive interaction in any pharmacological space. One, a pair of 
structurally similar drugs could have low similarity in activity. Two, the activity profiles of two 
structurally similar drugs may be highly dissimilar or variant. These are used alternatively for 
characterizing the well known phenomenon of activity cliff [17,18]. However, as shown here, this 
choice of measurement becomes crucial if s is measured by only the commonly active targets of drugs 
and ignores the commonly unresponsive proteins. Thus, the activity variation may not totally indicate 
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the magnitude of similarity of drugs. I determine which of these behaviors is dominant in the present 
interaction space using the measures of s, d.  
 
4.21 Similarity and Dissimilarity in Activity 
The weighted adjacency matrices Ψ  and   of drug-drug interactions measure the magnitude of 
similarity and difference or variation in activity of drug pairs respectively. In the given 
pharmacological space, 0 ≤ Ψ"# ≤ 28;  0 ≤ "# ≤ 114 . As before, these interaction weights 
representing elements of Ψ and  are denoted by s and d respectively.  
 
4.22 Comparison in the Chemical Space 
This subsection examines how the measures vary on all pairs of drugs in different ranges of chemical 
similarity, c. Fig. 4.3 illustrates the structure-activity associations for s versus d in progressing 
windows of c. Detailed inspection suggests that although the averages of both s and d are more or less 
constant over the chemical space, in every window, the fractions of the weights of d found above 
average remain higher than fractions of weights of s found above average. These d weights tend to be 
higher in magnitude than s weights owing to constructions of s, d. While both s and d decline with c 
overall, it must be noted that the decrease in s occurs rather gradually and hence the cliff 
representation may be deficient. Further, the density of magnitudes (or number of points) found above 
average for s and d across each row of plots in Fig.4.3 is different. In all the subfigures, and 
particularly the ones in the intermediate region of the chemical space 0.3 ≤  ≤ 0.65, it is clear that 
the preponderance is more in the region marked by above average d than the corresponding region for 
s. This implies that a pair of structurally similar drugs is more likely to possess highly variant than 
highly similar activity.  
Intermittent spikes in activity variation occur in the intermediate range of chemical similarity  ∈
i0.3, 0.65j  or  ∈ i0.4, 0.65j with a dense layer of points beneath. This feature can be used to 
reasonably delineate the structure versus activity graphs from the perspective of activity variation. 
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Thus in terms of variation, the landscape maybe characterized as activity canyons or gorges depending 
on the steepness. This also applies to s but less distinctly. 
 
Fig. 4.3 (Left) Plotting s with c in four chemical similarity intervals (topmost to bottom in order) of [0.3, 0.5], [0.4, 0.6], 
[0.5, 0.7], [0.6, 0.8]. (Right) Plotting d with c in four chemical similarity ranges (topmost to bottom in order) of of [0.3, 
0.5], [0.4, 0.6], [0.5, 0.7], [0.6, 0.8]. The horizontal solid red lines correspond to the averages of s and d in the respective 
intervals of c. 
 
 
4.3 Structure Activity Quantification 
In general medicinal chemistry has relied on quantification of structure activity to obtain a function f 
such that, change in physiological activity= f (change in structure) [1]. Here the nature of the function 
and hence the landscape characterization would depend on whether similarity or variation was 
considered for quantifying biological activity. We are interested in the two dimensional interactions 
relating structure (c) and activity (s or d). Measures like sali have been applied to quantify activity 
cliffs. However, as discussed earlier, high sali could also arise from high c (low d) or low c (high d). 
The overall score can be misleading for identification of distinctive links with high c and high d. 
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Therefore, in this chapter, I present a probabilistic analysis of the each of the measures s and d jointly 
with c. This informs us of not only the significance of cliffs but also where (if at all) they are found in 
the chemical space. The main purpose of this representation is for finding the probability of 
occurrence of various levels of (extreme) deviations. In other words, for every pair of drugs, it 
quantifies: how distinctive and how probable?. This was addressed in chapter 3 experimentally by 
calculating the empirically observed probabilities of different (joint) categories of c,s and c,d. Here, I 
approach it with a predicted probability model. 
 
4.31 Predicted Probability 
The joint probabilities of structural or chemical similarity with activity variation and similarity are 
approximated using the probability distributions of these individual properties Eqs.(4.1)-(4.3).  
Assuming continuous distributions for the link weights as random variables for similarity (s), variation 
(d), chemical similarity (c), we can write the mathematical forms of the normalized probability 
distributions as 
% = 0.045"m  ± "m²(³                                4.1, 
 
% = 0.042 ´7©o(´7                           4.2, 
 
   % = * − 1"m  ± "m²()                       4.3. 
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The behaviors are shown in Fig.4.4. Here smin, cmin , dmin correspond to the minimum values of s, c, d 
respectively. We have dmin = 0 and for a well defined power-law distribution7, we consider  smin = 1, 
cmin = 0.004. 
This analysis is based on the distributions of s, d and c weights of all the links. Fig.4.4 shows the 
different kinds of probability distributions of drug-drug interactions in terms of % = , % = , 
% = . While s and c conform to a power law probability distribution, d follows an exponential 
distribution8 . Note that the distributions found are approximations used to provide a generalized 
prediction of the propensity of distinctiveness.  
 
                                                        
7 The power law approximations in Eqs. 4.1 and 4.3 are normalized and the constants are determined by 
regressing probability and activity measures (s and d) on a logarithmic scale. This is shown as an activity canyon 
characterization of the pharmacological topography [21]. 
8 The approximation in Eq. (4.2) is an exponential distribution. The constant  is obtained as the coefficient of 
regression log % ≈ . The semi log plot of log(P(d)) versus d is shown in Fig. 4.4.  
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Fig. 4.4 (Top) Probability of pairwise chemical or structural similarities P(C=c) on a log-log plot. The straight 
line approximates power law behavior on a range of c with exponent 3.6±0.14.  
(Middle) Probability of number of similar activities % =  on log-log plot. The straight line approximates power law 
behavior on a range of s with exponent 2.37±0.15. 
(Bottom) Probability of number of dissimilar activities or variation % =  on a semilog plot. The straight line 
approximates exponential behavior on a range of d with exponent 0.17±0.003. 
 
This indicates that probability of finding extremely large d diminishes much faster than corresponding 
to s, however, the magnitudes of d are much higher than those of s when  ≥ 0.3. Further, the power 
law exponents of c, s indicate that the second moment (indicative of the variance) of c is much higher 
than that of s, implying that s is more or less homogeneously distributed in the interaction space. 
In this interaction based predicted probability model, the joint probability % = µ ∩  = µ  or % = µ ∩  = µ for each pair of drugs specifies the chance of finding the level of distinctiveness 
shown by the interaction between that pair of drugs. s0 , c0 , d0  are parameters denoting magnitudes of 
s, c, d which we vary. In the same way, one can specify ranges of study @ ≤  ≤ F, @ ≤  ≤ F, @ ≤  ≤ F and find the corresponding probabilities (of finding links with weights in those ranges). 
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The calculations below give the probability of finding links exhibiting a given level of distinctiveness 
(or non-distinctiveness). 
 
If structure and activity are independently generated, then predicted joint probabilities are given  
by 
 
 
I provide the proof of the above statement in Appendix 3.1. 
The two measures are compared by computing the predicted probabilities of s and d above their 
respective averages  1  and  17 . This is done by comparing Eqs. (4.4) and (4.5) taking smin=1, 
cmin=0.004, dmin=0, @ = 1, F = ∞, @ = 17 , F = ∞, in different ranges of [c1, c2] as [0.3, ) [0.3, 
0.65], [0.65,) for the purpose of integration. The standard deviations of the link weights of s and d are 
respectively ¨ and ¨7. In the range of  ≥ 0.3, we have 1 = 1.62, ¨ = 2.95, 17 = 4.85, ¨7 = 7.53. 
The values of these averages and standard deviations are computed for all progressing windows along 
the chemical space.  
In order to compare s with d above their respective averages, we measure the predicted probability of 
finding  ≥ 1 + · ¨ and  ≥ 17 + ·¨7for j=0,1,2..  in the same chemical space. These are considered 
as measurements for the categories %8 ≥ 1 ∩ @ ≤  ≤ F9 and %8 ≥ 17 ∩ @ ≤  ≤
F9 for similar and variant activities respectively. Also calculated are the probabilities for 
standardized data where all the values of s and d are subtracted from their averages and divided by 
their standard deviations for a certain chemical space. Then the comparison is between the probability 
of finding s and d above their average=0 in all intervals of c. The probabilities calculated with the 
model for the categories j=0,1..8 for d are almost consistently and significantly higher than those for s. 
When they are not higher, the difference is insignificant. This is important and interesting to note and 
            %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = "m)(@"m³(@@@(³  − F@(³8@@()  − F@()9          4.4 
 %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = "m)(@ 0.042 8(´7: − (´7B98@@()  − F@()9          4.5 
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is given in Fig. 4.5. It must also be noted that c is considered at least equal to 0.3, links below which 
have little consequence for a meaningful analysis, as in chapter 2. 
 
 
 
Fig. 4.5 Variation of observed joint probabilities of  ∩  and  ∩  with the number of standard deviations, j.  
 
 
4.32 Validation 
First, the predicted probability formulas (derived in Eqs. 4.4,4.5) are validated for the entire data of 
1354 drugs by comparing the predicted probability with the observed probability for categories  ≥
1 +  ¨ and  ≥ 17 + ¨7 taking  ≥ 0.3. For this purpose, I take observations and compute 
predictions at n= 0, 0.2, 0.4,…9.  I use the averages and standard deviations for the entire (original) 
data and compute RMSE for judging the agreement between the predicted probability (ppred) and 
observed probability (pobs) for s and d. ¸u¹º = »∑ 6<¼C(6½¾¿ B#(@#  , j = 1,2… Note that the observed 
values are computed by considering the number of links sharing both properties of being within the 
given range of c and s (or d). The bivariate condition is expressed as % ∩  = %|%. If we 
find the joint probability of the two properties in a particular range of c then P(c)=1. 
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RMSE is as low as 0.0001 and 0.0006 for calculations of d and s respectively. It is remarkable that 
while generalized predictions are made with the assumption of independence of s and c, and, d and c 
on all pairs of drugs, they confirm the observed dominance of above average d values. Fig. 4.6 shows 
the agreement between observed and predicted values for d. 
Figs. 4.7, 4.8 show the steady decrease in predicted and observed probabilities with increasing levels 
of screening (or n), the patterns are close to each other. 
 
 
 
Fig. 4.6 Observed and predicted probabilities (scaled) for  ≥ 17 + ¨7 and  ≥ 0.3 plotted with n using 
the original data (left). Observed versus predicted probabilities showing a good agreement (right).  
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Fig. 4.7 Predicted and observed joint probabilities of  ≥ 1 for  ≥ 0.3 plotted with n. The observations are 
scaled by 40000. 
 
 
Fig. 4.8 Predicted and observed joint probabilities of  ≥ 17  for  ≥ 0.3 plotted with n. The observations are 
scaled by 100000.  
 
 
Next, I validate the predictions of the probability of distinctiveness using the system of drugs of the 
nervous system. This system consists of data on activity of 146 drugs on 219 protein targets. The 
probability distributions of interaction weights measured using pairwise s, d, c values for this system 
 66 
are similar to those shown in Fig. 4.4 but the patterns are not identical. The probability distributions of 
s and d are indicated as power law and exponential respectively (as before) in Figs. 4.9, 4.10, there 
may be some difference in the patterns, exponents. 
While the probability distribution of c is the same as that obtained above, the distributions of s and d 
show approximately similar patterns as there may be some deviations. As before, I compare the 
observed probabilities with the predicted probabilities using the formulas, for categories  ≥ 1 +  ¨,  ≥ 17 + ¨7 taking  ≥ 0.3. Using the information for this drug ensemble "m=0.0089,"m = 1,"m = 0,  1 = 1.18, ¨ = 3.63, 17 = 16.67, ¨7 = 13.39, I show in Fig. 4.11 the agreement between 
observations and predictions for d. RMSE is 0.002 and 0.0006 for s and d calculations respectively. 
Notably, there is good agreement between observations and predictions despite the deviations9 from 
the assumptions and conditions involved in the construction of the formulas.  
                                                        
9 I might digress a little at this point to expand on the significance of the quantitative assessment of this 
information. The data put as a network has information on the drug generation carried on for a long time and we 
analyze the state to which the discovery has led. Thus, it is more about using this evidence to understand the 
evolutionary process. The network structure constructed out of an ensemble of drugs performing different 
functions may represent an integrative system- of individuals in the society or neural ensemble. The structure 
and biology of drugs in the larger ensemble are more diverse than in the one consisting of the drugs of the 
nervous system. In the networks constructed with both ensembles, drugs perform different functions and are 
connected by their structural and functional similarities or variations. Therefore, the integrative action of these 
topographies may be indicative of the evolution and the structural functionalism, and that the principles of this 
collectivism are the same for different or larger ensembles that may be created with time, similar to the cells in 
the democratic nervous system [29, 30]. Quantitative analysis of the given system is known to yield crucial 
information on evolution, for instance, the evolved regulatory processes in a cell or protoplasm established 
through “a harmonic relation between progressive events of the physiological dynamics of the cell”. Researchers 
[30] have focused on subjecting “the physiological properties of the cell to the analytical mode of quantitative 
studies with their time-progressions in velocities, as against a mass estimation verified through experiments”. 
Moreover, “the plant protoplasm has fundamental features of elasticities of various kinds with which it adjusts a 
harmonic progression of vital phenomena”.   
In the networks constructed, there may be drugs whose presence governs the collection significantly. However, 
with the constant addition and changes of drugs, the topographical changes would remain insignificant for a 
duration, due to a balance but the decisions in clinical preparation and marketing may become perceivably 
biased, gradually. These changes may not affect the conditional distributions to the extent of affecting the 
predictions on distinctiveness, and the samples considered maybe representative. Identification of distinctiveness 
in this case becomes vital for effective drug usage. 
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Fig. 4.9 Logarithmic plot of similarity in activity, s and the probability P(s) for the drug network of the Central 
Nervous System. The straight line has a regression coefficient~ 1.47. 
 
 
Fig. 4.10 Semilog plot of similarity in activity, d and the probability P(d) for the drug network of the Central 
Nervous System. The two straight lines indicate double scaling in the region. 
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Fig. 4.11. Predicted versus observed probabilities for (1) s and (2) d for n=0, 0.2, 0.4,..9. The observations are 
scaled by a factor and the slopes of the straight lines are 1.06 (1) and 1.22 (2). RMSE is 0.0021 in (1) and 
0.0006 in (2). 
 
 
 
 
 
4.33 Hypotheses Tests 
This subsection uses hypothesis testing to establish whether or not d dominates s by comparing 
observed probabilities (@, F) in regions spanning the chemical space 0.3 ≤  ≤ 1. The tests are listed 
below. Tests 1-3 show this comparison for 0.3 ≤  ≤ 1. Comparisons between different regions are 
given in tests 4-5. Test 6 gives the significance of variation as a refined filter of rare distinctive 
interactions. I report the test results along with significance level À, 
 
1. @ = % ≥ 0.3 ∩  ≥ 1,  F = % ≥ 0.3 ∩  ≥ 17 
p2 > p1, À < 0.01 
2.    @ = %0.3 ≤  ≤ 0.65 ∩  ≥ 1,  F = %0.3 ≤  ≤ 0.65 ∩  ≥ 17 
 p2 > p1, À < 0.01 
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      3.    @ = % ≥ 0.65 ∩  ≥ 1,  F = % ≥ 0.65 ∩  ≥ 17  
p2 > p1, À ~0.1 
4. @ = %0.3 ≤  ≤ 0.65 ∩  ≥ 1,  F = % ≥ 0.65 ∩  ≥ 1 
p1 > p2, À <0.05 
      5.     @ = %0.3 ≤  ≤ 0.65 ∩  ≥ 17,  F = % ≥ 0.65 ∩  ≥ 17 
p1 > p2, À < 0.05 
      6.    @ = % ≥ 0.65 ∩  ≤ 1,  F = % ≥ 0.65 ∩  ≥ 17 
p1 > p2, À < 0.01. 
 
Testing Methodology 
 
Two statistical tests are employed in order to test the significance of the difference between the 
observed probabilities associated with activity variation and similarity. They are described below. 
 
4.331 McNemar test for Comparing Proportions of s and d in a Chemical Region 
I apply McNemar’s test [31] to compare the relative frequencies (or probabilities) of s and d above 
their averages in the same chemical region  ∈ i@, Fj . This test is suitable for comparisons of the 
two measurements made on the same links. The contingency table for a given chemical region is 
  ≥ 17  < 17  ≥ 1 Á@ ÁF  < 1 Ás ÁÂ 
 
If Á@ + ÁF + Ás + ÁÂ = Á, we test whether or not marginal probabilities are equal : Á:ÃÁBÁ =Á:ÃÁÄÁ  
and 
ÁÄÃÁÅÁ =ÁBÃÁÅÁ  The null and alternative hypotheses can be written as 
H0: ÁF = Ás 
H1: ÁF < Ás  (frequency of  ≥ 17 is greater than that of  ≥ 1 in the given chemical region) 
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H0 is rejected in favor of H1 at the level of significance À  if ÁB(ÁÄBÁBÃÁÄ > Ç@F or if the binomial 
probability % ≥ Ás|Á = ÁF + Ás,  = 0.5 ≤ À. The comparisons made here suit the design of the 
analysis, hence no corrections are required.  
 
4.332 Paired t test  
This test is used to compare the average of the difference between probabilities @ = %@ ≤  ≤F ∩  ≥ 1 + · ¨  and F = %@ ≤  ≤ F ∩  ≥ 17 + ·¨7  observed (pairwise) at 
j=0,1,...8.  All the probabilities so computed can be generalized as @ = %@ ≤  ≤ F ∩  ≥ 1 
and F = %@ ≤  ≤ F ∩  ≥ 17 . These probabilities represent the results obtained by two 
different measures of interaction distinctiveness- s, d. In this way, we consider the variation of 
probabilities in the space above the average sampled at increasing number of standard deviations.    
 
We can test the null hypothesis H0 of equality of probabilities on average against one-sided alternative 
H1  
H0: 〈Δ〉 = 0 
H1: 〈Δ〉 < 0 or H1: 〈Δ〉 > 0 
with the test statistic,  = ÉÊË/mat significance level À = 0.05 for n-1 d.f. Here Δ represents the vector 
of differences, p1 - p2 ,  ¨É is the standard deviation of Δ and sample size n=9 here. The null hypothesis 
of no difference is rejected in favor of alternate H1 if the observed t is greater than the critical value of 
test statistic i.e. t > tc (0.05,8). This is applied for comparing probabilities of s and d in different 
chemical regions.  
 
Results of Hypothesis testing  
Results of the first three tests confirm that variant activity behavior dominates the similar activity 
behavior of the drug pairs consistently in the chemical space. The probability of finding above average 
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d magnitudes is more than that of finding above average s magnitudes in the region  ≥ 0.65, but the 
difference is less significant. The intermediate region of the chemical space 0.3 ≤  ≤ 0.65 marks the 
transitional regime when structural similarity starts being positively associated with d more than with 
s. Distinctiveness emerges here. Tests 4, 5 indicate that d and s decrease with increase in c. However, 
d significantly dominates s in both proportion and magnitude particularly in the intermediate chemical 
region. The paired t test is applied to compare these probabilities as they specify the effect of changing 
the level or range of c of interactions on their s and d weights. Test 6 establishes the advantage of d as 
a potential filter of distinctive interactions. Few above average d weights (32.5%) are higher in 
magnitude than 75% of below average s weights (Fig.4.12(i)-(iii)). This helps to identify all the rarely 
occurring distinctive interactions, most of which are not revealed with s but are crucial for 
characterization of activity landscape. Further, d yields distinctiveness at multiple levels of hierarchy 
set by criterion of the number of standard deviations above the average.  
Most distinctive interactions occur between vitamins and medicines curing ailments of classes such as 
central nervous system or dermatological in nature. Several less similar interactions filtered as 
distinctive, include compound pairs from distinct classes. Fig.4.13((i),(ii)) shows structural similarity 
of Sitagliptin and Nefazodane that affect insulin release and the nervous system, respectively. 
Interestingly, highly variant interactions are fewer and more distinctive as they include drugs and their 
structural analogs belonging to the same class but performing intricately different functions. 
Fig.4.13((iii)-(vi)) shows structurally similar Loxapine and Amoxapine affect the nervous system but 
Amoxapine is more versatile. Felodipine and Clevidipine are analogs for curing hypertension but 
Clevidipine treatment is more advanced. Thus, activity variation calculations are advantageous for 
identifying medicinal analogs that provide more specialized treatments for same kinds of ailments. 
The activities of such medicinal analogs typically vary a lot. This measure is particularly helpful in 
making finer distinctions between medicines having apparently similar treatments. It can therefore 
identify selective interactions, which would ensure a better matching of drugs to desirable treatments.  
 
 72 
Tests1-3 and 6 use McNemar test. Test 6 compares d as a filter for highly distinctive drug interactions 
with s. We compare the probabilities @ = % ≥ 0.65 ∩  ≤ 1 −  ¨ and F = % ≥ 0.65 ∩  ≥
17 + ¨7 , n=0,1,2.. For n=1, @ = 0  and F = @@@Fµ = 0.09. The d measure yields maximally 
distinctive interactions as n is increased, implying distinctiveness at multiple levels. Fig.4.12(iii) 
indicates this, and for n=1, I report the pairs of drugs that are most distinctive. The proportion and 
nature of interactions filtered are significantly different from that obtained with s.  
 
 
 
 
 
 
(i). 
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Fig. 4.12 (i) Network of 91 distinctive interactions determined by s below average 
 (ii). Network of 39 distinctive interactions determined by d above average.  
(iii)  Network of 11 distinctive interactions determined by d by calculation for   ≥ 17 + ¨7 . The medicine links 
are (Lysine-Ornithone), (Adenosine monophosphate-Adenosine triphosphate), (Vitamin A- Alitretinoin), 
(Vitamin A- Tretinoin), (Vitamin A- Isotretinoin), (Propoiomazine-Aceprometazine), (Loxapine-Amoxapine), 
(Dicloxacillin-Cloxacillin), (Pseudoephidrine-Ephedrine), (Tioconazole-Miconazole), (Felodipine-Clevidipine). 
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(iv). 
 
(v).  
 
 
(vi). 
 
  
Fig. 4.13 (i). Sitagliptin- used for control of type 2 diabetes mellitus, increased release of insulin. 
 
(ii). Nefazodone-analogous to Sitagliptin but affects central nervous system, has a palliative action. 
 
(iii). Loxapine-antipsychotic drug. 
 
(iv). Amoxapine- analogous to Loxapine but used for many other neurotic disorders and sedation.  
 
(v). Feldopine- calcium channel blocker for moderate hypertension.  
 
(vi). Clevidipine- analogous to Feldopine, is calcium channel blocker, but for advanced treatment of blood 
pressure. 
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4.4 Implications of the Characterization 
There are two contributions of the analysis in this chapter. One is a methodological contribution as it 
provides a mathematical basis for identifying distinctive interactions. The predicted probability 
analysis introduced here is based on simple assumptions but predicts the overall distinctiveness in 
various chemical regions to a reasonable accuracy. The second contribution is the canyon 
representation of the activity landscape of drugs or as we refer to it, the pharmacological topography. 
This representation is appropriate for the probabilistic analysis of distinctiveness because the two 
measures of similarity and variation are on highly different scales in the data. When similarity of 
activity is considered as given by the commonly active targets, some medicinal pairs may show both 
distinctiveness and non-distinctiveness and cliff representation is not sufficient.  
In the present pharmacological space, distinctive interactions are more probable than non-distinctive 
interactions. Non-distinctive interactions are regular as they conform to the similarity principle. 
Distinguishing among the distinctive interactions requires precision. The range of d is much higher 
than that of s. Quantitative comparison of the landscape reveals that structural and biological 
similarities, two a priori independent manifestations of drug interactions, are unevenly associated and 
maybe complementary. The presence of distinctiveness is highlighted by both s and d. As chemical 
similarity increases, both measures decrease. However, the decrease in s is more significant than that 
in d, as d maintains its above average value. Activity variation is a more suitable measure for 
characterization of the pharmacological interaction space than activity similarity10. Intermittent rises in 
d with chemical similarity maybe interpreted as activity canyons or gorges of varying levels. In this 
representation, the rises in both measures can be assessed relative to their respective ranges of 
magnitudes and compared across all pairs. The rises in activity similarity and variation are interpreted 
as increase in non-distinctiveness and distinctiveness respectively, characterized as activity canyons 
instead of cliffs. Therefore, distinctiveness is a general term that may represent abrupt deviations in the 
landscape as cliffs or canyons depending on the method of measurement. Moreover, the canyon 
                                                        
10 Appendix sections 3.1-3.3. 
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representation allows for the quantitative analysis of ‘how distinctive and how probable?’ 11 , 
demarcating the pharmacological subspace for finding distinctiveness. These rises in activity variation 
are probable12 all along the chemical space and more distinct than drops in s. The predicted probability 
model introduced in this chapter helps in identifying distinctive interactions and the probability of 
their occurrence in the landscape. The crucial merit of this approach is that whatever the assumptions 
and considerations or probability distributions in the construction of the formulas maybe, the 
predictions would also apply to data that are different in nature. The model helps in identifying 
distinctive drug associations that are not only significant and rare but also less apparent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
11 Multilevel distinctiveness is captured in this model by allowing a specification of the levels of c, s, d of the 
interactions. According to the Eqs. 4.4, 4.5, the probability of an interaction being distinctive (or non-distinctive) 
can be found in the range i, ∞j, i, ∞j, i, ∞j.  
12 The probability at the level s, c (or s, d) is given by the predicted estimate Ì = &@@(³@() (or = &F(´7@()) 
as Í, * are greater than 1, and &@, &F are constants in Eqs. 4.4, 4.5. Further, if  = µ, then the estimates using 
both measures can be compared with mean square error of Ì|  and Ì|   as the optimum prediction 
criterion: uÎ = ÏÎ + DÎF . Thus the optimal prediction (optimum uÎ ) by the measures depends on the 
variance and bias generated with their estimates Ì, Ì. Now Ï8Ì9 = &@FµF@()Ï@(³ and 
 Ï8Ì9 = &FFµF@()Ï8(´79.  
Using Taylor’s expansion, Ï@(³ = 1@(³ − 0.5Í1 − Í1(³(@Ï  and Ï8(´79 = (´ÐC +0.5F(´ÐCÏ. As we know, s is distributed as Pareto power law with 2 < Í < 3 for which the variance 
diverges in the limit of infinite size of the network and would be large for finite size networks. And as we know 
that d has an exponential distribution. Its variance ~ (F,  > 0, is finite. Therefore, for any limited or even large 
bias, using the efficiency of the two measures for an estimate of the predicted probability defined as Ï8Ì9/Ï8Ì9, it turns out that d would be better and more reliable measure for an optimal prediction. 
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Chapter 5 
 
INFORMATION, IMPLEMENTATION, AND MEASUREMENT 
 
The predicted probability model for distinctiveness developed in the previous chapter was shown to 
rely on the probability distributions of the two properties considered for distinctiveness (c, s) or (c, d). 
It was able to account for the observed distinctiveness despite the assumption of independence of the 
probabilities of the two interaction attributes involved, and the approximations applied. If the 
interaction of a pair of drugs is distinctive, then it possesses both high chemical similarity and highly 
variant (or less similar) activity.   Is the knowledge of the distribution of chemical similarity of links 
between drugs indicative of the nature of their similar or variant activity (s or d) distributions? It 
would be interesting to investigate this. I apply information theoretic measures [32, 33] to find the 
mutual dependence of the pair of variables or properties- (c, s) or (c, d). Using mutual information, one 
may infer whether and how much the joint distribution of probabilities of these variables is similar to 
the products of their marginal distributions. Further, it gives the relative entropy or the amount of 
information associated with a property. Here, it can be used to infer whether or how much knowing 
chemical similarity of a link reduces the uncertainty of s and d attributed to the link. This can provide 
a justification for the using both attributes simultaneously for classifying the interactions as 
distinctive13. 
 
 
 
                                                        
13 Conditional probability % ≥ 17| ≥ µ = Ñ7ÒÐC∩ÒÓÑÒÓ . If d and c are independent features of a connection, % ≥ 17| ≥ µ = % ≥ 17. Distinctiveness involves d and c, however, some connections may have both 
high d and high s. Using Bayes theorem with all the features of a connection, probability of distinctiveness is % ≥ 17 ∩  ≥ µ = ∑ %"% ≥ 17 ∩  ≥ µ|"" , summing on all discrete levels of s observed. It should 
be obvious that if a connection has a high level of s, then the measure of distinctiveness is not independent of 
non-distinctiveness. Therefore, how good a measure d is for distinctiveness would depend on P(s). If higher 
levels of s occur with very low probability, then the non-distinctiveness in the sum can be ignored and d is an 
adequate measure. We can think similarly for s. This emphasizes the importance of knowing the probability 
distributions of all features of a connection. 
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5.1 Mutual Information, Uncertainty, and Relative entropy 
Mutual Information of two random variables X and Y is given by 
Ô; Õ = ∑ ∑ G, 
 log \ 6n,Ö6n6Ö_              5.1.nÖ   
p(x,y) is the joint probability distribution. Considering X=c, Y=s, their joint probability distribution can 
be computed. 
The range for analysis of this data is @@ ≤  ≤ FF and @@ ≤  ≤ FF and all the links are 
distributed in the discrete categories 0.3 ≤  ≤ 0.9 , 0 ≤  ≤ 28 , 0 ≤  ≤ 114.  Using Eq.(5.1), I 
compute the empirical mutual information by summing over all values which gives Ô,  = 2.16 ×
10(Â  and Ô,  = 6.56 × 10(× . These values are very close to 0, the value expected when the 
variables are independent. Fig. 5.1 shows the variation of Ô = 0.3,  ≥ 1 +  ¨ and Ô = 0.3,  ≥17 + ¨7 with n. Increasing n increases the level at which mutual information for distinctiveness and 
non-distinctiveness is measured by Ô,  and Ô,  respectively.  
 
 
Fig. 5.1 Mutual information Ô ≥ 0.3,  ≥ 1 +  ¨ and Ô ≥ 0.3,  ≥ 17 + ¨7 plotted with n. 
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The mutual information decreases as the level of identification of distinctiveness becomes more 
selective, i.e. as n increases. This would imply that specific information about the levels of each of the 
attributes c, d (or distinctiveness of) a link becomes important. In other words, for finding links at high 
levels of distinctiveness, the relevance of both c and d increases. It is interesting that the mutual 
information of non-distinctive interactions also decreases as the level of screening for non-
distinctiveness increases but it is still higher than I(c, d).  
I use a related measure, the Uncertainty coefficient U to determine the predictability of one variable 
when the other is given [32]. It is normalized mutual information. In general, for variables X, Y, 
Ø|Õ = Ô, ÕÙ                              5.2 
 
where Ù = − ∑ ÚGlog ÚGn  is the entropy associated with X. 
The computed U(c|s), U(s|c), U(c|d), U(d|c) plotted with n show that apart from U(c|s) (and U(c|d) to 
some extent), all other quantities are small. Thus there is some (at least a small, finite) predictability 
that can be achieved for levels of s and d when c is specified but it is not true the other way around. If 
s or d levels are given, we cannot be sure which c level the links belong to.  
 
This can be further investigated by finding the relative entropy of probability distribution of chemical 
similarity of links with respect to that of activity similarity (and activity variation). Kullback-Leibler 
divergence (KLD) gives the increase of information [33] when c instead of s (or d) is used to 
characterize distinctiveness. Symmetrized KLD is useful for analyzing the differences in the 
contribution of links to the divergence according to the levels of their features c, s, d. In the context of 
distinctiveness, this involves comparison of probabilities of links by categorization of their weights w 
in terms of two properties - Û  (the weight of chemical similarity) and Û  (or Û7 ),  weights of 
similarity (or variation) in activity. This procedure is also used in text categorization research. All the 
links are analyzed individually and the weights of all attributes given by Û, Û, Û7 are considered for 
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every link. It is examined how probable it is to find weights such as these. These probabilities are then 
compared. The assignment is done by sampling the data into broad categories of  ≥  =
0.3, 0.5, 0.7. In each sample, 
let  = %Û = ,   = %Û =  and 7 = %Û7 = , then 
 
Ü>,  = ∑  −« "m;  log \6Ý6¿_                       5.3      
Ü>,  = ∑  −« "m; 7 log \6Ý6C_                      5.3D.  
By assigning the links to the categories and computing the probabilities, I compute KLD(c, s) and 
KLD(c, d) using Eqs. 5.3a, 5.3b. It must be noted that the categories of s and d are further divided as 
 ≥ 1 +  ¨ and  ≥ 17 + ¨7  for n=0,1,2... Also, since the links are dealt with individually, the 
categories of c are continuous as they appear in the data. It turns out that KLD(c, s) decreases much 
slower than KLD(c, d) and KLD(c, d) is very small.  
 
 
Fig. 5.2 Variation with n of KLD(c,s) (Top) and KLD(c, d) (Bottom) for data samples obtained by removing 
redundant links having  ≥  = 0.3, 0.5, 0.7. 
0 1 2 3 4 5 6 7 8 9 10
0
1000
2000
3000
n
K
L
D
(c
;s
)
 
 
const = 0:3
const = 0:5
const = 0:7
0 1 2 3 4 5 6 7 8
0
5
10
15
20
n
K
L
D
(c
;d
)
 
 
const = 0:3
const = 0:5
const = 0:7
 84 
 
KLD decreases in all cases shown in Fig.5.2. The decrease in KLD implies decrease in relative 
entropy. It is not surprising that it is the highest when const = 0.3 because it is the most dense category 
with most of the links having chemical similarity in this range. However, it is interesting that in this 
and all other ranges specified by const = 0.5, 0.7 the KLD(c, d) is always much lower than KLD(c, s) 
and vanishes quickly with increase in n. If  = 0 and, or 7 = 0 then the interactions (or links) are 
not distinctive. If  = 0 and, or  = 0 then the similarity principle is contradicted. Moreover these 
links contribute nothing to KLD. A decrease in KLD would mainly occur with increase in such cases 
because it becomes rarer to find links of high s and high d as n increases. It may be interesting to note 
that few links that contribute to these categories – high c, s and high c, d are rare, and more 
importantly, it is rarer to find highly distinctive links (high c, d) than to find highly non-distinctive 
links (high c, s).  
 
For quantifying the rareness of such distinctive links, I define a rareness coefficient,  ≥ 7(@, for 
 ≠ 0, 7 ≠ 014. This means that the links that correspond to the least probable chemical space as 
well as the least probable d, score the highest on rareness or are the rarest distinctive. Rareness is also 
a measure of the information content in the link and the uncertainty of its attributes (c, d)15. By 
replacing 7 with  in calculation of r, we can obtain the rareness of the non-distinctive interactions. 
The rareness of the distinctive interactions can be ranked using this scheme (fixed by r). Figs. 5.3-5.5 
below show the number of distinctive interactions divided into quadrants of rareness, r depending on 
, 7.  
 
                                                        
14 This requirement is to avoid a singularity. If either  = 0 or 7 = 0 or both then such a link is infinitely rare, 
meaning it would be impossible to find this level of distinctiveness (specified by c, d) in the present data. 
15 This rareness coefficient can be considered proportional to the information content in the interactions. Taking 
logarithm of r, we can write log  = − log  − log 7 . Thus for an interaction with highly probable attributes 
[32], the uncertainty is very low, but it is very high when at least one of the attributes of the interaction is highly 
improbable. 
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Fig. 5.3 Plot of 7 = %Û7 =  ≥ 17 on the vertical axis with  = %Û ≥ 0.3 on the horizontal axis for all 
links in the data sampled at const=0.3. The quadrants divide the 419 distinctive interactions on the basis of their 
rareness, indicating least and most rare quadrants. 
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Fig. 5.4 Plot of 7 = %Û7 =  ≥ 17 on the vertical axis with  = %Û ≥ 0.5 on the horizontal axis for all 
links in the data sampled at const=0.5. The 86 distinctive interactions are represented and the least and most 
rare regions of the plot are indicated. 
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Fig. 5.5 Drug index plot of drugs involved in the distinctive interactions shown in Fig.5.4 for 7 = %Û7 =  ≥17 and  = %Û ≥ 0.5 in the data sampled at const=0.5. 
  
For const=0.3, most distinctive interactions score highly on rareness but both the number of most 
distinctive interactions and r reduces for const=0.5. In the category of most highly distinctive 
interactions, which is specified by const=0.7 and  ≥ 17, the 6 rare (not the rarest of all) distinctive 
interactions are  
(Adenosine monophosphate- Adenosine triphosphate), (Flucloxacillin- Dicloxacillin), (Adreparin-
Amoxapine), (Alitretinoin- Tretenoin), (Tretenoin-Isotretenoin), (Pseudoephedrine-Ephedrine). 
The medicines constituting these pairs are structurally similar and their functionalities are not identical 
but quite similar, as they perform intricately different functions.   
In the category of most highly non-distinctive interactions (conforming most to the similarity 
principle) which is specified by const=0.7 and  ≥ 1, the 4 rare (not the rarest of all) non-distinctive 
interactions are 
(Adenosine monophosphate- Adenosine triphosphate), (Nisoldipine-Nifedipine), (Eszopiclone-
Zopiclone), (Adreparin-Amoxapine). 
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The medicines constituting these pairs are identical in their functioning as per the description in the 
drug bank. Note that the pairs (Adenosine monophosphate- Adenosine triphosphate) and (Adreparin-
Amoxapine) are both distinctive and non distinctive. This is different from the observation in chapter 
3. This points to the importance of method of analysis as it may render the interpretation of 
distinctiveness as subjective. 
 
 
5.2 Perturbation and its Implications for Identifying Distinctive Interactions 
Drug discovery often relies on optimization algorithms such as minimum, maximum spanning trees 
for finding structurally diverse compounds and in other applications [33]. Such medicinal compounds 
may or may not be functionally similar and it is important to investigate that for distinctiveness. I will 
close this thesis with a discussion of how and whether distinctiveness is affected by perturbations. In 
quantum mechanics, a system is perturbed slightly so that the deviations in the energy and eigenstates 
represent corrections to states of the original system. In chapter 3, we saw the effect of retaining links 
possessing a minimum level of c in the network using un-weighted adjacency matrices of , , . 
Different kinds of distinctive interactions were identified by modifying the networks. Distinctiveness 
was also studied using weighted matrices of cd. High value of cd on links indicated high level of 
distinctiveness but the level of distinctiveness was tuned by the parameter: number of standard 
deviations above mean. Those interactions that survived in distinctive categories of large n were not 
only the ones possessing greatest distinctiveness but also the most robust. In this last section, I apply a 
perturbative approach to investigate the robustness of distinctive interactions, and to thereby assess the 
sensitivity of the system (drug network) to the perturbations.  
Specifically, I iteratively perturb the weight matrix W=cd by reducing the elements of the matrix each 
time by a small fraction. I wish to analyze the impact this has on our perception of distinctiveness. If 
the elements of the weighted adjacency matrix W are perturbed uniformly16 as Þ"# → Þ"# − Þ"#  ∀, · 
                                                        
16 This is simple. It would be useful to consider other perturbations. 
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for 0 <  < 1, for a total of 3  iterations, then the corresponding change in eigenvalues of W at the 
end of 3 iterations is proportional to Δm3 = 1 − 1 − m3. This is given by the Theorem in Appendix 
4. It must be noted that the value p that would cause an optimum (or minimum) deviation depends on 
the number of iterations.  I apply different values of  (Corollary 1 in Appendix 4 gives the optimum 
perturbation criterion and the optimum relation between p and ′ ) for ′ iterations to look for any 
modifications in classification of distinctive interactions at different levels of perturbation. The 
minimum level of perturbation represents the weakest disturbance to the system and any modifications 
in distinctiveness would represent corrections in identification. 
I compare the principal eigenvector of W before and after perturbation. The maximum eigenvalue 
«n of the matrix decreases steadily as p increases. See Fig. 5.6. As for the perturbation applied 
previously, that is removing links having c<const, the decrease in «n with increase in restriction on 
the retainment of links is expected in accordance with the Theorem (Appendix 2) and shown in 
Fig.5.7. In Fig. 5.8, I plot the drop in «n due to perturbation of individual vertices, keeping rest of 
the network fixed. The vertex whose perturbation causes maximum drop would satisfy Corollary 2 in 
Appendix 4. When we apply the minimum perturbation using p=0.2, 3 = 4, the decrease is shown to 
be the greatest for the vertex representing drug Adenosine triphosphate17. In the decreasing order of 
their impacts on «nÞ , the drugs representing the vertices are Adenosine monophosphate, 
Adenosine, Vidrabine, Riboflavin, S-Adenosinemethionine. This minimum perturbation applied to the 
elements of any other drugs does not result in any change in «nÞ. It must be noted that most of 
these are constituents of  highly distinctive interactions indicated Fig. 3.17 except Riboflavin. 
 
                                                        
17 This result would remain the same for p=0.2, 3 = 1 applied in accordance with the corollary. 
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Fig. 5.6 Variation of «n  of W with the perturbation parameter p. 
 
Fig. 5.7 Variation of «n  of W with const (Top) and of the probability p(c≥const) with const (Bottom). 
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Now, I remove the redundant links for which c<0.3 from the network and analyze the effect of 
perturbing  Þ → Þ − Þ  once and 3 > 1  times, on the apparent distinctiveness that emerges. I 
(minimally) perturb the matrix using p=0.2 once and for 3 = 4 times, and p=0.3 for 3 = 2 times. To 
compare the distinctiveness before and after perturbation, I filter the links in the perturbed network 
whose weights are n standard deviations higher than the average of the weights in the unperturbed 
matrix, W. Fig. 5.9 compares the number of distinctive interactions in the perturbed and unperturbed 
network as n increases. The perturbation reduces «n and shifts the components of the corresponding 
eigenvector from negative to positive. Evidently, the decrease in number of distinctive interactions 
filtered is sharper for the perturbed network and this allows us to analyze the difference. For instance, 
for n=34, we are able to retrieve the 15 most highly distinctive interactions using the perturbed W. 
This is much lower as compared to 90 distinctive interactions predicted by the unperturbed W using 
the same criterion for filtering, which is  ≥ 17 +  ¨7 . The identification of distinctiveness is 
highly sensitive to such perturbations.  
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Fig. 5.8 The largest eigenvalue of the W plotted with the index of the individual drug whose elements are 
perturbed using p=0.2, 3 = 4.  The solid line represents the largest eigenvalue of the unperturbed weight 
matrix. 
 
Moreover, the 15 most highly distinctive interactions are not only the same as those identified in 
Fig.3.17, but also highly robust, as confirmed by this analysis. The drugs constituting these are the 
also ones causing significant drops in largest eigenvalue discussed above. Fig. 5.10 shows that the 
impact of the minimum perturbation applied p=0.3, 3 = 2 is smaller. Hence the number of distinctive 
interactions decreases slowly with increase in n which makes many other distinctive interactions 
perceptible (as distinctive). For instance, for n=34, we obtain 22 distinctive interactions and for n=30, 
there are 43 distinctive interactions including those 15 interactions observed above. This shows how 
sensitive the system is to change in perturbation and therefore points to the adaptive nature of the 
interpretation of what is distinctive. The network in Fig. 5.11 shows all of these, and the 43-15=28 
interactions are also indicated. Here, an additional interaction identified as (L-Aspartic acid, L-Serine) 
was not considered distinctive in Fig.3.17. It is interesting to see interactions between drugs affecting 
the same classes such as the nervous system but having functional diversity. There are also few 
interactions affecting ailments of different classes. One can continue this analysis for various levels of 
optimal perturbation and observe the number and kinds of distinctive interactions that can remain 
classified as distinctive for any kind of perturbation. 
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Fig. 5.9 Number of distinctive interactions filtered as links whose weights obey the criterion  ≥ 17 +  ¨7 
plotted with n. p=0.2. 
 
 94 
 
Fig. 5.10 Number of distinctive interactions filtered as links whose weights obey the criterion  ≥ 17 +  ¨7 
plotted with n. p=0.3, 3 = 2. 
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Fig. 5.11 Network of distinctive interactions filtered using the criterion  ≥ 17 +  ¨7  for n=30. The 
distinctive interactions in addition to those indicated in Fig.3.17 are: (L-Aspartic acid, L-Ornithine), (L-Aspartic 
acid, L-Serine), (L-Aspartic acid, L-Alanine), (Adenosine monophosphate, Vidrabine), (Adenosine 
monophosphate, Adenosine), (L-Ornithine, L-Cysteine), (L-Serine, Glycine), (Succinic acid, Azelaic acid), 
(Succinic acid, Aminolevulinic acid), (Glycine, L-cysteine), (Glycine, Aminocaproic acid), (Glycine, 
Aminolevulinic acid), (Glycine, Dihydroxyaluminium), (Vitamin A, Alitretenoin), (Vitamin A, Tretenoin), 
(Vitamin A, Isotretenoin), (Lorazepam, Oxazepam), (Amitriptyline, Notriptyline), (Amitriptyline, Olapatidine), 
(Amitriptyline, Cyclobenzaprine), (Alprazolam, Trizolam), (Prochlorperazine, Chlorpromazine), 
(Chlorpromazine, Triflupromazine), (Dextromethorphan, Levorphanl), (Olapatadine, Doxepin), (Clonazepam, 
Nitrazepam). 
 
 
It is fascinating that high number of distinctive interactions obtained with the unperturbed matrix in 
this case reveals a lot of hidden distinctiveness. For instance, there are interactions such as 
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(Adenosylmethionine, Adenosine monophosphate) that are highly distinctive but sensitive to 
perturbations of the system. This is crucial for any analysis of distinctiveness in drug interactions.  
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CONCLUSIONS 
 
This thesis quantitatively analyzes the structure activity associations in a large collection of drugs and 
their targets. In particular, I study distinctive interactions between pairs of drugs occurring in the 
pharmacological activity landscape. I consider interactions between pairs of drugs as connections and 
assess them using three attributes of their chemical similarity (c), magnitudes of activity similarity (s) 
and activity variation (d). A preliminary analysis of the drug network constructed through 
commonality of targets between drugs gives limited evidence for the prevalence of similarity 
principle. Few drugs with many targets share similar activity with many drugs but few of these drug 
connections have high chemical similarity.  
Distinctive pairs are identified as those with high c and d or with high c and low s. This means that 
there are medicines having selective treatments and distinctiveness distinguishes these selective 
interactions. While previous studies on activity cliffs have considered similarity and variation in 
activity as alternate specifications for quantifying distinctiveness, their methods do not define the level 
of distinctiveness well. Furthermore, they consider activity similarity as determined exactly by 
variation. I point out here that they may not necessarily be indicative of each other. In the given drug 
ensemble, I observe that the pairwise interactions are distributed across multiple levels or categories of 
c and s or c and d jointly. The probability of finding links in upper ranges of both of the combined 
categories decreases, yet, it is nonzero. This shows the presence of multilevel distinctiveness and non 
distinctiveness in the pharmacological landscape.  
The present dissertation focuses on a generalized prediction or identification of multilevel 
distinctiveness based on the data. In this respect, the analyses make two important contributions. First, 
is a methodological contribution in the form of a predicted probability model for identifying 
distinctive interactions, commonly studied as activity cliffs in literature. It is also able to predict the 
distinctiveness observed in a pharmacological space that may not be identical to the one considered for 
its construction. Further, the method is general as it can be applied in evaluation using different kinds 
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of information available, e.g. if the information on activity is both binary and continuous. The second 
contribution is toward a new characterization of the pharmacological topography in the form of 
activity canyons. It is associated with the probabilistic analysis of distinctiveness and helps to filter 
drug interactions at varying levels of distinctiveness and non-distinctiveness. It emphasizes the 
relevance of both measures for enhancing our perspective on distinctive interactions. It facilitates 
identification of distinctive interactions and the region of the chemical space to find them. The 
methodology aims to rigorously quantify the distinctiveness that can occur in diverse forms. This is 
helpful as the presence of these deviations is known to hinder the quantitative structure activity 
modeling. Accurate identification of distinctive interactions would decrease the risk of indiscriminate 
prescription and use of medicines by health care providers and consumers respectively.   
Activity cliffs have been studied in detail in past research. These aberrations make it harder to 
coherently generalize the quantitative association between changes in physiological activity and 
structure, which is vital for medicinal chemists. Methods applied can influence the decision process of 
preparing fresh drugs and drug development through identification of distinctive pairs. The deviations 
in activity due to small chemical innovations have the potential of producing inventions in medicine. 
Thus, distinctiveness could be an externality for the drug industry. 
The interpretation of the topography of pharmacological interaction space can vary according to the 
choice of measurement of c, s, d. I illustrate this with a probabilistic analysis of the pharmacological 
space which considers the probability of each of the measures s and d jointly with c. The consistency 
between observations and predictions corroborates that structural (c) and biological (s or d) properties 
can be considered as independently generated for studying the discontinuities in the landscape. A 
distinctive interaction can be measured either as high c, d or high c and low s. The almost contrasting 
construction of both measures results in a much higher range and distribution of magnitudes of d than 
of s. This affects the quantitative assessment of the interaction landscape, particularly for 
distinguishing amongst structure-activity functions displayed by drugs. As I show here, it is less 
significantly likely for a pair of drugs with high structural similarity to act similarly than oppositely on 
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a target. Further, the decrease in similar activity along the chemical space lacks the steepness of a cliff. 
In the given pharmacological space, high d dominates the chemical space in terms of not only 
magnitudes but also the probabilities. This behavior is mostly observed in the intermediate range of c. 
This is a transitional regime as it marks the increasing significance of d. The formulation shows the 
estimation of the prediction using d is more efficient. 
As c increases, interactions corresponding to high d are relatively rare and more distinctive than those 
of low s. This facilitates preparation of analogs for intricately specified treatments. Low s interactions 
can occur between drugs affecting different classes. However, distinctive interactions of high d are 
rarer and occur between structural analogs aimed to treat same kinds of ailments with increasingly 
intricate specifications. Such analogs providing advanced or versatile treatments of same kinds of 
ailments vary highly with respect to their activity profiles. The differentiation between these kinds of 
drugs requires precision, and is highly crucial because a medicine may be rendered less effective in 
improving health if its treatment is not restricted to the particular treatment it is designed for. It is 
important to note that such associations are identified with high d instead of low s.  
Based on the complex nature of structure-activity relationship study, this analysis aims to suggest an 
alternative characterization resulting from mathematical and statistical formulations.  A crowded 
valley of magnitudes with intermittent spikes of variation in the chemical subspaces, may be 
characterized as activity canyons or gorges. This can be an encouraging sign for diversity in drug 
development. For instance, if a minor change in structure gives rise to an analog, then the two may be 
active on different kinds of targets more often than not. The sizes of their activity profiles may also be 
quite different. The methods provide a basis for practitioners and pharmacologists to identify 
distinctive interactions and the region of chemical space that they are probable to occur in.  
Finally, the interpretation of distinctiveness and non-distinctiveness in the activity landscape is 
sensitive to perturbations and the ranges of measures used. At a given level of c, the distinctive 
interactions obtained with low s are different from those obtained with high d. This dissertation is an 
attempt to highlight the role of the techniques and criteria in evaluating distinctiveness in drug 
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interactions. They can render this concept of distinctiveness open to multiple interpretations and often 
adapting to the choice of measurement. I hope that this analysis would contribute to better health by 
meting out drugs to the desirable therapeutic targets. It is a crucial consideration for making 
quantitative assessments that would have the potential to affect contemporary and future research, 
drug discovery and development.  
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Appendix 
 
 
Mathematical Proofs 
 
 
1.1 Derivation of áw and áx  in Eqs. (2.3), (2.4). 
 
Sketch of the derivation: The two quantities H@, HF can be derived using the procedure [22, 23] of 
random graphs, for the bipartite network with both kinds of vertices possessing power law distribution. 
The generating functions of &6, &7 are  
 
µG = â"ã:?näå :æ:Aâ"ã:?äå :æ:A   and µG =
â"ãB?näå :æBA
â"ãB?äå :æBA       and    
@G = â"ã:å:?näå :æ:Anâ"ã:å:?äå :æ:A and @G =
â"ãBå:?näå :æBA
nâ"ãBå:?äå :æBA    respectively.  
 
H@ = µ31@3 1  and HF = µ31@31i@3 1jF     
 
Substituting the above expressions in those of H@ and HF , and considering x=1, we get the required 
expressions for H@, HF in Eqs. (2.3), (2.4). 
 
1.2 Derivation of ç~ in Eq. (2.5). 
Sketch of the derivation: 
I derive the probability distribution for the network [22] with the generating functions, 
èµG = µ8@G9 
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 which implies                   èµG = â"ã:â"ã:?äå :æ:A é
â"ãBå:?näå :æBA
nâ"ãBå:?äå :æBAê 
 
Since *@>1, >): ±( :æ:² ≈ ë*@ , ë is called Riemann zeta function, but this is highly sensitive to 
small shifts or variations in ( :æ: [which is not =1 as shown in Fig. 2.1], and similarly for *F. 
Probability of k links can be found by the derivatives ; = @;!  7ìíÓ7nì  at x=0.  
 
 
Let   
â"ãBå:?näå :æBA
nâ"ãBå:?äå :æBA = î , @ = 7íÓ7n = @â"ã:?äå :æ:A â"ã:å:ïï î/G    at  x = 0. 
 
 7BíÓ7nB = @â"ã:?äå :æ:A \â"ã:å:ïï 7Bï7nB + â"ã:åBïïB î/GF − â"ã:å:ïïB î/GF_ at x=0. 
 
7BíÓ7nB = @â"ã:?äå :æ:A é>):(@ é @â"ãBå:?äå :æBAê >)B(@ ±(
:æB² FsãBå: + â"ã:åBäå :æ:(â"ã:å:äå :æ:FãBå:B ê for x=0 
 
 
 
Now, the computation of ( :æ: is subject to errors, and I consider the least estimate in the interval 
around the standard error, so that  
â"ã:åB?äå :æ:A(â"ã:å:?äå :æ:AFãBå:B ≪ 1. This is also feasible owing to the 
susceptibility of the function to small changes in inputs. Hence, I retain only the first terms involving 
>):(@ in all the derivatives and ignore all higher order terms. This is done for convenience of solving. 
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7ÄíÓ7nÄ = @â"ã:?äå :æ:A \â"ã:å:ïï 7Äï7nÄ + â"ã:åÄïïÄ î/GF + â"ã:åBïïB 77n î/GF + â"ã:åBïïB 7ï7n 7Bï7nB +ℎ. . _  
 
Again, the higher order terms h.o. are ignored and only first term involving >):(@is retained and then 
approximated. The reason is the same, because *@ ≈ *F ≈ 2, >):(s é @â"ãBå:?äå :æBAê ≪ 1 and similarly 
for other higher order terms. 
 
This inspection of terms for k=1,2,3 can be used for k>3, and thus retaining only the first terms, the 
approximate connectivity distribution is as given in Eq.(2.5), 
 
; = @;! >):(@ é @â"ãBå:?äå :æBAê >)B(@ ±(
:æB² &! & + 1()BÃ@. 
 
 
 
2. Link retaining procedure 
Theorem: A weighted adjacency matrix W is perturbed by retaining only the links with chemical 
similarity c ≥ const, then the maximum eigenvalue «n of the perturbed matrix Þ′ satisfies «nÞ3 ≤ «nÞ, where  = c ≥ const is the probability of finding links at the level of 
chemical similarity const or greater. 
Proof:  It is known that for any real symmetric matrix such as W having eigenvalues   and 
eigenvectors x, the quantity  
 = GõÞGGõG  
is maximized for the maximum eigenvalue «nÞ and the corresponding eigenvector, that is when 
 = «n = nö÷nnön .  
Imposing the condition of retaining only those links in W that possess chemical similarity c ≥ const, 
the number of links is reduced and so is the average connectivity <k> of W. The average connectivity 
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is calculated for the unweighted adjacency matrix derived from W in which the non-zero elements of 
W are considered as 1 (or connected).  Upon doing so, the new perturbed matrix Þ′ has average 
connectivity < & > ′  and the maximum eigenvalue «nÞ3 . From the distribution of chemical 
similarity of links, we can find the required probability, p using information from the chemical 
similarity adjacency matrix C. Assuming that the links of every node in the network (of size N) are 
formed independently, we can say that all nodes have approximately (1-p)N nodes with whom they do 
not have connections and approximately pN nodes with whom they retain the connections after 
perturbation. A node in W having k links is reduced to having &3 = & links in Þ′ after perturbation, 
so the average connectivity of Þ′ is   < & >3≈  < & > . 
Define an indicator function Ι"# = 1 C"# ≥  ; Ι"# = 0  C"# <  . This specifies the un-
weighted adjacency matrix for the constraint applied on retaining of links before after perturbation as Ι 
and Ι′  respectively. Thus Þ3 = Þ ∘ Ι′  is obtained by taking the entrywise product (or Hadamard 
product) of the two matrices. Considering  «n as the spectral radius of the matrices in this case, it is 
established that   «nÞ ∘ Ι′ ≤   «nÞ «nΙ′ . Considering the maximum eigenvalue as 
roughly equal to the average connectivity of the network (for any graph, < & >≤ «n ≤maximum 
connectivity),  
 «nΙ′ ≈  «nΙ  
which proves that 
«nÞ3 ≤ «nÞ. 
 
 
 
3.1 Joint probability computation 
 
If structure and activity are independently generated, then predicted joint probabilities are given by 
            %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = "m)(@"m³(@@@(³  − F@(³8@@()  − F@()9          
 %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = "m)(@ 0.042 8(´7: − (´7B98@@()  − F@()9        
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Proof: Since the structure and activity are independently generated, using probability distributions of 
P(c) and P(s) from above, the joint probabilities approximate to  
 %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = %@ ≤  ≤ F%@ ≤  ≤ F 
 =  û µ.µÂ×©o  \ 3©o_(³ ′ û )(@©o  \ 3©o_() ′B:B:                                     (1). 
 
Similarly, using probability distributions of P(c) and P(d), we obtain 
  %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = %@ ≤  ≤ F%@ ≤  ≤ F = û 0.042 ´7©o(´7ü′ û )(@©o  \ 3©o_() ′B:7B7:                               (2). 
 
Solving equations (1) and (2) we obtain 
 %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = "m)(@"m³(@@@(³  − F@(³8@@()  − F@()9                 (3). 
 %8@ ≤  ≤ F ∩ @ ≤  ≤ F9 = "m)(@ µ.µÂF´ 8(´7: − (´7B98@@()  − F@()9             (4). 
 
 
Eqs. (3) and (4) give the predicted probabilities of simultaneously finding structural and biological 
similarity, and structural similarity and distance in a range, respectively. 
 
3.2 Predicted probability and range 
The lower bound on the predicted probability calculated above using two variables (s and c) or (s and 
d) works differently for both measures s and d. 
Using Chebyshev inequality, %8@@ ≤ c@ ≤ @F ∩ F@ ≤ cF ≤ FF9 ≥ 1 − ∑ ý""q@,F ,       
 ý" = ÂÊ©BÃFÐ©(©:Ã©BB©B(©:B  , 1" , "¨ are the mean and variance of variable c" respectively.  
Taking c@ = , cF = , we find the probability in any range of these variables is uncertain because s 
has a power law distribution with very high variance, and by the inequality it would imply that the 
probability of finding c and s in any range can be any value between 0 and 1. However, when c@ =  
and cF = , the variances of c and d are finite and we can adjust the ranges of the variables to control 
for the uncertainty of the estimate. 
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However, this technique is of little use if the domain is restricted to high or extreme values of c, s, d 
for distinctiveness. The explicit calculation in 3.1 helps in quantifying the extremes of both variables 
jointly. 
 
3.3. The effect of choice of technique for discerning distinctiveness and non-distinctiveness 
In the predicted probability model introduced above, the levels of distinctiveness or non-
distinctiveness are specified by the levels or ranges of c, s, d, assuming independence of structure and 
activity. The two estimates of predicted probability of distinctiveness are þ = %8 ≥ µ ∩
 ≥ 1 +  ¨9 = r% ≥ 1 +  ¨,  taking r = % ≥ µ. 
And þ7 = %8 ≥ µ ∩  ≥ 17 + ¨79 = r% ≥ 17 + ¨7,   
According to Chebyshev inequality, %| − 1| ≥  ¨ ≤ 1/F and %| − 17| ≥ ¨7 ≤ 1/F. This 
gives the bounds on finding the probability of distinctiveness and non-distinctiveness at the extremes 
using both measures s and d in the same chemical space. Now assuming a constant  =  "¨, with i as a 
symbol for s and d, the probability of finding large values are bounded above as %| − 1| ≥  ≤
¨F/F for s, and, %| − 17| ≥  ≤ ¨7F/F for d. As the variance of s if very high and would become 
infinite as the system size becomes infinitely large, the prediction in any interval around the mean or 
away from it or in the tails of the distribution, is highly arbitrary for all values of , r. 
In contrast, ¨7F is measurable and finite. Thus it is possible to find  so that || ≥ |¨7| ensures a finite 
predicted probability (for n>1) of finding highly distinctive or non-distinctive interactions. Now to 
consider both distinctiveness and non-distinctiveness that can be discerned by using d, the predicted 
probability of finding either kind of interaction between drugs can be written as þ7 = r%| −17| ≥  ≤ r 7¨F/F.  
This facilitates the specification of an interval around the mean: || ≥ r|¨7| . The equality 
corresponds to a greater maximum of the probability that can be estimated. The values on the right 
outside of this interval would correspond to distinctive interactions and those to the left would 
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correspond to the non-distinctive interactions. The probability of finding them is lower, meaning they 
are rarer. Moreover, higher chemical similarity values are less probable and the interval around the 
mean that distinguishes highly distinctive from non-distinctive diminishes. When µ  is relatively 
lower, it is the other way around. This indicates a tradeoff between chemical similarity and ¨7 for 
discernibility of distinctiveness. Interestingly, high distinctiveness (and high non-distinctiveness) will 
be more discernible and rarer at very high levels of both attributes. 
 
4.  
Theorem: If the weighted adjacency matrix W, with eigenvalues Λ is iteratively perturbed as Þ"#3 =
Þ"# − Þ"#   ∀, · for 0< p < 1, then at the end of n iterations, the change in eigenvalues ‖ΔΛ‖ ∝ |Δm| 
where Δm = 1 − 1 − m. 
Proof sketch: 
The perturbations grow successively as follows. 
 
For the first step  = 1, Þ"#3 = Þ"#1 − , 
 
for  = 2, Þ"#33 = Þ"#3 − Þ"#3 = Þ"#1 − F = Þ"# − 2Þ"# + FÞ"#, 
 
for  = 3, Þ"#333 = Þ"#33 − Þ"#33 = Þ"#1 − s = Þ"# − 3Þ"# + 3FÞ"# − sÞ"#, 
. 
. 
. 
and therefore inductively generalizing for  = , Þ"# → Þ"#Δm where Δm = 1 − 1 − m. 
It is well established that the perturbation of W to Þ + ΔW results in change in eigenvalues as 
‖ΔΛ‖ = ‖(@‖‖‖‖ΔW‖  (where X is the set of eigenvectors of the matrix).  
After m=n iterations, as shown above, ‖ΔW‖ = |Δm|‖W‖ and therefore ‖ΔΛ‖ ∝ |Δm|. 
 
Corollary 1: (Optimum perturbation). 
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For the weighted adjacency matrix W to be perturbed at least once by proportion p, the corresponding 
change would be  
Δm ≤  
Proof: It is known from theorem above that when the elements of W are perturbed by a fraction p, such 
that 0<p<1 then the change in the maximum eigenvalue (after n perturbations) is proportional to Δm =1 − 1 − m. Since this is a monotonic function in p and n, we can approximate the change to be as 
low (or as high) as 	 so that 	 > 0. This means that we require 
 
1 − 1 − m = 	 
 
which implies that  = 
@(

@(6. For  ≥ 1, solving the inequality log1 − 	log1 −  ≥ 1 
 
we get 	 ≤ . This means if the perturbation is applied  ≥ 1 times, then Δm ≤ . 
 
Corollary 2: When the link weights of individual vertices in W are perturbed, the perturbation of the 
link weights of the vertex i maximizes the decrease Δ«nÞ if there is an indicator function Ô 
defined as  Ô"3# = 1   ∀· if 3 =   and Ô"3# = 0   ∀·  if 3 ≠  , so that «nÔ ≥ «nÔ3   ∀3 =
1,2 … . 
Proof: 
The weighted adjacency matrix W is perturbed using an indicator function Ô = Ô  which specifies 
the unweighted adjacency matrix such that the elements of dr row and column corresponding to 
dr vertex are equal to 1 and the other elements in the matrix are 0. It is symmetric. Therefore, the 
perturbation is Þ"# → Þ"# − Þ°Ô"#  and its magnitude is ‖∆Þ‖ = ||‖Þ°Ô‖ ≤
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||‖ÔõÔ‖‖ÞõÞ‖. Since the norm of the indicator function is the maximum eigenvalue, ‖ÔõÔ‖ =
«nÔ. For any vertex 3 ≠ , the indicator function Ô3 = Ô3 satisfies ‖Ô3õÔ′‖ = «nÔ′. Now, the 
magnitude of perturbation to W is greatest due to a perturbation of link weights of vertex i when 
«nÔ ≥ «nÔ′. Thus from the theorem the drop in maximum eigenvalue ∆«n is greatest when 
the links of vertex i are perturbed for same level of perturbation |Δm|.  
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